NovaBay Pharmaceuticals, Inc. NBY Financial Statement Data


2025 Q2

Submissions

Field Row 1 Row 2
adsh 0001437749-25-017064 0001437749-25-010730
cik 1389545 1389545
name NOVABAY PHARMACEUTICALS, INC. NOVABAY PHARMACEUTICALS, INC.
sic 2834 2834
countryba US US
stprba CA CA
cityba EMERYVILLE EMERYVILLE
zipba 94608 94608
bas1 2000 POWELL STREET, SUITE 1150 2000 POWELL STREET, SUITE 1150
bas2
baph (510) 899-8800 (510) 899-8800
countryma US US
stprma CA CA
cityma EMERYVILLE EMERYVILLE
zipma 94608 94608
mas1 2000 POWELL STREET, SUITE 1150 2000 POWELL STREET, SUITE 1150
mas2
countryinc US US
stprinc DE DE
ein 680454536 680454536
former
changed
afs 4-NON 4-NON
wksi 0 0
fye 1231 1231
form 10-Q 10-K
period 20250331 20241231
fy 2025 2024
fp Q1 FY
filed 20250515 20250402
accepted 2025-05-15 11:08:00.0 2025-04-02 17:17:00.0
prevrpt 0 0
detail 1 1
instance nby20250331_10q_htm.xml nby20241231_10k_htm.xml
nciks 1 1
aciks

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
cik Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings.
name Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date.
sic Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business.
countryba The ISO 3166-1 country of the registrant's business address.
stprba The state or province of the registrant’s business address, if field countryba is US or CA.
cityba The city of the registrant's business address.
zipba The zip code of the registrant’s business address.
bas1 The first line of the street of the registrant’s business address.
bas2 The second line of the street of the registrant’s business address.
baph The phone number of the registrant’s business address.
countryma The ISO 3166-1 country of the registrant's mailing address.
stprma The state or province of the registrant’s mailing address, if field countryma is US or CA.
cityma The city of the registrant's mailing address.
zipma The zip code of the registrant’s mailing address.
mas1 The first line of the street of the registrant’s mailing address.
mas2 The second line of the street of the registrant’s mailing address.
countryinc The ISO 3166-1 country of incorporation for the registrant.
stprinc The state or province of incorporation for the registrant, if countryinc is US or CA.
ein Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States.
former Most recent former name of the registrant, if any.
changed Date of change from the former name, if any.
afs Filer status with the SEC at the time of submission:
1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned.
wksi Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement.
fye Fiscal Year End Date, rounded to nearest month-end.
form The submission type of the registrant’s filing.
period Balance Sheet Date, rounded to nearest month-end.
fy Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8).
fp Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year.
filed The date of the registrant’s filing with the Commission.
accepted The acceptance date and time of the registrant’s filing with the Commission.
prevrpt Previous Report – TRUE indicates that the submission information was subsequently amended.
detail TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount).
instance The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol.
nciks Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing.
aciks Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information.

Numbers

adsh ddate tag value uom qtrs version segments coreg footnote
0001437749-25-017064 20240331 Adjustments To Additional Paid In Capital Down Round Feature Adjustment Related To Preferred Stock -380000.0000 USD 1 0001437749-25-017064 Class Of Stock= Series C Preferred Stock; Equity Components= Retained Earnings;
0001437749-25-010730 20231231 Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition 0.0000 USD 4 us-gaap/2024 Equity Components= Common Stock; Title Of Individual= Employees And Directors;
0001437749-25-010730 20241231 Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition 148000.0000 USD 4 us-gaap/2024 Title Of Individual= Employees And Directors;
0001437749-25-010730 20231231 Amortization Of Debt Discount Premium 1690000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Assets 9034000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20241231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations 0.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect -2240000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations -2619000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Disposal Group Including Discontinued Operations -206000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Common Stock Value 49000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20241231 Down Round Feature Adjustments Related To Common Stock Warrants 1005000.0000 USD 4 0001437749-25-010730
0001437749-25-010730 20231231 Fair Value Adjustment Of Warrants -170000.0000 USD 0 us-gaap/2024 Class Of Warrant Or Right= May2023 Warrants;
0001437749-25-010730 20241231 Fair Value Adjustment Of Warrants 21000.0000 USD 4 us-gaap/2024 Class Of Warrant Or Right= March2024 Warrant; Scenario= Reporting Date March312024;
0001437749-25-010730 20241231 Fair Value Adjustment Of Warrants -28000.0000 USD 4 us-gaap/2024 Class Of Warrant Or Right= March2024 Warrant; Scenario= Stockholder Approval May282024;
0001437749-25-010730 20241231 Gain Loss On Sale Of Business -865000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Income Loss From Heldfor Sale Assets 111000.0000 USD 4 0001437749-25-010730
0001437749-25-010730 20231231 Increase Decrease In Inventories -162000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Increase Decrease In Inventories -99000.0000 USD 4 us-gaap/2024 Disposal Group Classification= Disposal Group Heldforsale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Wound Care;
0001437749-25-010730 20241231 Increase Decrease In Inventories 272000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Increase Decrease In Inventories -183000.0000 USD 4 us-gaap/2024 Disposal Group Classification= Discontinued Operations Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Dermadoctor;
0001437749-25-010730 20241231 Increase Decrease In Inventories -15000.0000 USD 4 us-gaap/2024 Disposal Group Classification= Disposal Group Heldforsale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Wound Care;
0001437749-25-010730 20231231 Increase Decrease In Operating Lease Liability -319000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Increase Decrease In Operating Lease Liability -119000.0000 USD 4 us-gaap/2024 Disposal Group Classification= Discontinued Operations Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Dermadoctor;
0001437749-25-010730 20231231 Liabilities Of Disposal Group Including Discontinued Operation Current 698000.0000 USD 0 us-gaap/2024 Disposal Group Classification= Discontinued Operations Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Dermadoctor;
0001437749-25-010730 20241231 Modification Of Warrants 69000.0000 USD 4 0001437749-25-010730
0001437749-25-010730 20241231 Net Cash Provided By Used In Operating Activities Continuing Operations -5183000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Net Income Loss 0.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001437749-25-010730 20231231 Net Income Loss Available To Common Stockholders Basic -16967000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Noncash Expense Incurred To Obtain Consent Of Secured Note Holders 368000.0000 USD 4 0001437749-25-010730
0001437749-25-010730 20241231 Noncash Gain On Changes In Combined Derivative Liability 18000.0000 USD 4 0001437749-25-010730
0001437749-25-010730 20231231 Operating Expenses 10186000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Operating Lease Liability Current 368000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Operating Lease Right Of Use Asset 1296000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Payments Of Debt Issuance Costs 181000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Payments To Acquire Property Plant And Equipment 6000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Preferred Stock Shares Issued 0.0000 shares 0 us-gaap/2024 Class Of Stock= Series C Preferred Stock;
0001437749-25-010730 20231231 Preferred Stock Shares Outstanding 6000.0000 shares 0 us-gaap/2024 Class Of Stock= Series B Preferred Stock;
0001437749-25-010730 20231231 Proceeds From Warrant Exercises 400000.0000 USD 0 us-gaap/2024 Class Of Warrant Or Right= The December2023 Warrants;
0001437749-25-010730 20241231 Reclassify Private Placement Warrants 100000.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= March2024 Warrant; Equity Components= Additional Paid In Capital;
0001437749-25-010730 20241231 Reclassify Private Placement Warrants 212000.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= The December2023 Warrants;
0001437749-25-010730 20241231 Retained Earnings Accumulated Deficit -183457000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Revenue From Contract With Customer Including Assessed Tax 1273000.0000 USD 4 us-gaap/2024 Product Or Service= Other Products;
0001437749-25-010730 20241231 Revenue From Contract With Customer Including Assessed Tax 9781000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Revenue From Contract With Customer Including Assessed Tax 7200000.0000 USD 4 us-gaap/2024 Product Or Service= Avenova Product;
0001437749-25-010730 20241231 Revenue From Contract With Customer Including Assessed Tax 0.0000 USD 4 us-gaap/2024 Product Or Service= Neutrophase;
0001437749-25-010730 20241231 Revenue From Contract With Customer Including Assessed Tax 9747000.0000 USD 4 us-gaap/2024 Product Or Service= Total Product Revenue;
0001437749-25-010730 20231231 Stockholders Equity 3314000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Stock Issued During Period Value Conversion Of Convertible Securities 728000.0000 USD 4 us-gaap/2024 Conversion Of Stock By Unique Description= Conversion Of Series C Preferred Stock To Common Stock; Equity Components= Additional Paid In Capital;
0001437749-25-010730 20231231 Stock Issued During Period Value Conversion Of Convertible Securities 0.0000 USD 4 us-gaap/2024 Conversion Of Stock By Unique Description= Conversion Of Series C Preferred Stock To Common Stock; Equity Components= Common Stock;
0001437749-25-010730 20231231 Stock Issued During Period Value Conversion Of Convertible Securities -728000.0000 USD 4 us-gaap/2024 Conversion Of Stock By Unique Description= Conversion Of Series C Preferred Stock To Common Stock; Equity Components= Preferred Stock;
0001437749-25-010730 20231231 Stock Issued During Period Value Conversion Of Convertible Securities 0.0000 USD 4 us-gaap/2024 Conversion Of Stock By Unique Description= Conversion Of Series C Preferred Stock To Common Stock; Equity Components= Retained Earnings;
0001437749-25-010730 20241231 Stock Issued During Period Value Conversion Of Convertible Securities 0.0000 USD 4 us-gaap/2024 Conversion Of Stock By Unique Description= Conversion Of Series C Preferred Stock To Common Stock;
0001437749-25-010730 20241231 Stock Issued During Period Value Reverse Stock Splits 0.0000 USD 4 0001437749-25-010730
0001437749-25-010730 20241231 Stock Issued In Connection With Exercise Of Warrants Shares 2041814.0000 shares 4 0001437749-25-010730 Class Of Warrant Or Right= Prefunded Warrants2024 Public Offering;
0001437749-25-010730 20241231 Stock Issued In Connection With Exercise Of Warrants Value 0.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= The2024 Warrant Reprice Transaction; Equity Components= Retained Earnings;
0001437749-25-010730 20241231 Accounts Notes And Loans Receivable Net Current 389000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20241231 Accounts Payable Current 623000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Adjustments To Additional Paid In Capital Down Round Feature Adjustment Related To Preferred Stock 0.0000 USD 4 0001437749-25-010730 Class Of Stock= Series C Preferred Stock; Equity Components= Common Stock;
0001437749-25-010730 20241231 Adjustments To Additional Paid In Capital Down Round Feature Adjustment Related To Preferred Stock 0.0000 USD 4 0001437749-25-010730 Class Of Stock= Series C Preferred Stock; Equity Components= Common Stock;
0001437749-25-010730 20241231 Adjustments To Additional Paid In Capital Modification Of Warrant 69000.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= The2024 Warrant Reprice Transaction;
0001437749-25-010730 20231231 Adjustments To Additional Paid In Capital Reclassifications Of Warrants 1360000.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= May2023 Warrants;
0001437749-25-010730 20231231 Adjustments To Additional Paid In Capital Reclassifications Of Warrants 0.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= May2023 Warrants; Equity Components= Preferred Stock;
0001437749-25-010730 20241231 Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition 0.0000 USD 4 us-gaap/2024 Equity Components= Preferred Stock; Title Of Individual= Employees And Directors;
0001437749-25-010730 20231231 Allowance For Doubtful Accounts Receivable Current 3000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20241231 Allowance For Doubtful Accounts Receivable Current 3000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20241231 Amortization Of Financing Costs And Discounts 904000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Amortization Of Financing Costs And Discounts 800000.0000 USD 4 us-gaap/2024 Debt Instrument= Original Issue Discount Senior Secured Convertible Debentures;
0001437749-25-010730 20231231 Assets Held For Sale Not Part Of Disposal Group Current Other 63000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Cash And Cash Equivalents At Carrying Value 2924000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20241231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 907000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 3606000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Common Stock Shares Authorized 150000000.0000 shares 0 us-gaap/2024
0001437749-25-010730 20241231 Common Stock Shares Authorized 150000000.0000 shares 0 us-gaap/2024
0001437749-25-010730 20231231 Derivative Liability Issued With Notes 0.0000 USD 4 0001437749-25-010730
0001437749-25-010730 20241231 Disposal Group Including Discontinued Operation Assets Noncurrent 0.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Earnings Per Share Basic -139.1400 USD 4 us-gaap/2024
0001437749-25-010730 20230430 Fair Value Adjustment Of Warrants 400000.0000 USD 0 us-gaap/2024 Class Of Warrant Or Right= The2023 Private Placement;
0001437749-25-010730 20240630 Fair Value Adjustment Of Warrants -47000.0000 USD 0 us-gaap/2024 Class Of Warrant Or Right= May2023 Warrants;
0001437749-25-010730 20240630 Fair Value Adjustment Of Warrants -16000.0000 USD 0 us-gaap/2024 Class Of Warrant Or Right= The Amended November2022 A1 And A2 Warrants;
0001437749-25-010730 20241231 Fair Value Adjustment Of Warrants 56000.0000 USD 4 us-gaap/2024 Class Of Warrant Or Right= The December2023 Warrants; Scenario= Reporting Date December312023;
0001437749-25-010730 20241231 Gross Profit 6481000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Income Loss From Heldfor Sale Assets 404000.0000 USD 4 0001437749-25-010730
0001437749-25-010730 20231231 Increase Decrease In Accounts Payable And Accrued Liabilities -32000.0000 USD 4 us-gaap/2024 Disposal Group Classification= Discontinued Operations Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Dermadoctor;
0001437749-25-010730 20231231 Increase Decrease In Accounts Receivable 237000.0000 USD 4 us-gaap/2024 Disposal Group Classification= Discontinued Operations Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Dermadoctor;
0001437749-25-010730 20241231 Increase Decrease In Accounts Receivable -291000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Increase Decrease In Other Operating Assets -15000.0000 USD 4 us-gaap/2024 Disposal Group Classification= Discontinued Operations Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Dermadoctor;
0001437749-25-010730 20241231 Inventory Net 765000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20241231 Liabilities And Stockholders Equity 3423000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20241231 Liabilities Current 2843000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20241231 Operating Income Loss -5839000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Operating Lease Right Of Use Asset Amortization Expense 341000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Other Assets Noncurrent 478000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Preferred Stock Shares Outstanding 5607.0000 shares 0 us-gaap/2024 Class Of Stock= Series B Preferred Stock; Subsidiary Sale Of Stock= The2021 Private Placement Program;
0001437749-25-010730 20241231 Preferred Stock Value 0.0000 USD 0 us-gaap/2024 Class Of Stock= Series C Preferred Stock;
0001437749-25-010730 20240731 Proceeds From Warrant Exercises 20000.0000 USD 0 us-gaap/2024 Class Of Warrant Or Right= Prefunded Warrants2024 Public Offering;
0001437749-25-010730 20241231 Reclassify Private Placement Warrants 212000.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= The December2023 Warrants; Equity Components= Additional Paid In Capital;
0001437749-25-010730 20231231 Repayments Of Convertible Debt 126000.0000 USD 0 us-gaap/2024 Debt Instrument= Original Issue Discount Senior Secured Convertible Debentures;
0001437749-25-010730 20241231 Repayments Of Convertible Debt 1990000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Revenue From Contract With Customer Including Assessed Tax 6100000.0000 USD 4 us-gaap/2024 Product Or Service= Avenova Product;
0001437749-25-010730 20231231 Revenue From Contract With Customer Including Assessed Tax 7805000.0000 USD 4 us-gaap/2024 Product Or Service= Avenova Spray;
0001437749-25-010730 20231231 Revenue From Contract With Customer Including Assessed Tax 10455000.0000 USD 4 us-gaap/2024 Product Or Service= Product;
0001437749-25-010730 20231231 Revenue From Contract With Customer Including Assessed Tax 0.0000 USD 4 us-gaap/2024 Product Or Service= Product And Service Other;
0001437749-25-010730 20241231 Revenue From Contract With Customer Including Assessed Tax 500000.0000 USD 4 us-gaap/2024 Counterparty Name= Mc Kesson Corporation; Product Or Service= Avenova Product;
0001437749-25-010730 20241231 Selling And Marketing Expense 4034000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Stockholders Equity -174849000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001437749-25-010730 20241231 Stockholders Equity -129000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Stock Issued During Period Shares Conversion Of Convertible Securities -1000.0000 shares 4 us-gaap/2024 Conversion Of Stock By Unique Description= Conversion Of Series C Preferred Stock To Common Stock; Equity Components= Preferred Stock;
0001437749-25-010730 20241231 Stock Issued During Period Shares Conversion Of Convertible Securities -1000.0000 shares 4 us-gaap/2024 Conversion Of Stock By Unique Description= Conversion Of Series C Preferred Stock To Common Stock; Equity Components= Preferred Stock;
0001437749-25-010730 20231231 Stock Issued During Period Value Conversion Of Convertible Securities 0.0000 USD 4 us-gaap/2024 Conversion Of Stock By Unique Description= Conversion Of Series B Preferred Stock To Common Stock; Equity Components= Retained Earnings;
0001437749-25-010730 20241231 Stock Issued During Period Value Conversion Of Convertible Securities 6000.0000 USD 4 us-gaap/2024 Conversion Of Stock By Unique Description= Conversion Of Series B Preferred Stock To Common Stock; Equity Components= Common Stock;
0001437749-25-010730 20241231 Stock Issued During Period Value Conversion Of Convertible Securities 0.0000 USD 4 us-gaap/2024 Conversion Of Stock By Unique Description= Conversion Of Series B Preferred Stock To Common Stock; Equity Components= Retained Earnings;
0001437749-25-010730 20241231 Stock Issued During Period Value Conversion Of Convertible Securities 2000.0000 USD 4 us-gaap/2024 Conversion Of Stock By Unique Description= Conversion Of Series C Preferred Stock To Common Stock; Equity Components= Common Stock;
0001437749-25-010730 20241231 Stock Issued During Period Value Reverse Stock Splits 0.0000 USD 4 0001437749-25-010730 Equity Components= Retained Earnings;
0001437749-25-010730 20240930 Stock Issued In Connection With Exercise Of Warrants Shares 2041814.0000 shares 3 0001437749-25-010730 Class Of Warrant Or Right= Prefunded Warrants2024 Public Offering;
0001437749-25-010730 20231231 Stock Issued In Connection With Exercise Of Warrants Value 101000.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= The2023 Warrant Reprice Transaction; Equity Components= Additional Paid In Capital;
0001437749-25-010730 20231231 Stock Issued In Connection With Exercise Of Warrants Value 0.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= The2023 Warrant Reprice Transaction; Equity Components= Preferred Stock;
0001437749-25-010730 20231231 Stock Issued In Connection With Exercise Of Warrants Value 0.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= The2023 Warrant Reprice Transaction; Equity Components= Retained Earnings;
0001437749-25-010730 20231231 Unsecured Debt Current 0.0000 USD 0 us-gaap/2024
0001437749-25-010730 20241231 Unsecured Debt Current 65000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20241231 Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 1005000.0000 USD 4 us-gaap/2024
0001437749-25-017064 20241231 Accrued Liabilities Current 581000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20250331 Accrued Liabilities Current 1780000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20240331 Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition 60000.0000 USD 1 us-gaap/2025 Equity Components= Additional Paid In Capital; Title Of Individual= Employees And Directors;
0001437749-25-017064 20250331 Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition 2000.0000 USD 1 us-gaap/2025 Title Of Individual= Employees And Directors;
0001437749-25-017064 20250331 Adjustments To Additional Paid In Capital Warrant Repurchase 1990000.0000 USD 1 0001437749-25-017064
0001437749-25-017064 20250331 Adjustments To Additional Paid In Capital Warrant Repurchase 0.0000 USD 1 0001437749-25-017064 Equity Components= Retained Earnings;
0001437749-25-017064 20241231 Assets Current 1935000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20241231 Cash And Cash Equivalents At Carrying Value 430000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20240331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect -1307000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20241231 Common Stock Par Or Stated Value Per Share 0.0100 USD 0 us-gaap/2025
0001437749-25-017064 20250331 Fair Value Adjustment Of Warrants 21000.0000 USD 1 us-gaap/2025 Class Of Warrant Or Right= March2024 Warrant; Scenario= Reporting Date March312024;
0001437749-25-017064 20240331 Income Loss From Continuing Operations Per Diluted Share -27.5400 USD 1 us-gaap/2025
0001437749-25-017064 20240331 Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity -989000.0000 USD 1 us-gaap/2025 Disposal Group Classification= Discontinued Operations Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Dermadoctor;
0001437749-25-017064 20240331 Income Loss From Discontinued Operations Net Of Tax Per Diluted Share -2.4100 USD 1 us-gaap/2025
0001437749-25-017064 20240331 Net Income Loss -3214000.0000 USD 1 us-gaap/2025 Equity Components= Retained Earnings;
0001437749-25-017064 20250331 Net Income Loss 0.0000 USD 1 us-gaap/2025 Equity Components= Preferred Stock;
0001437749-25-017064 20240331 Noncash Expense Incurred To Obtain Consent Of Secured Note Holders 368000.0000 USD 1 0001437749-25-017064
0001437749-25-017064 20250331 Payments Of Debt Issuance Costs 0.0000 USD 1 us-gaap/2025
0001437749-25-017064 20240331 Preferred Stock Convertible Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 380000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20240331 Preferred Stock Shares Outstanding 26.0000 shares 0 us-gaap/2025 Class Of Stock= Series B Preferred Stock; Subsidiary Sale Of Stock= The2021 Private Placement Program;
0001437749-25-017064 20250331 Preferred Stock Shares Outstanding 1000.0000 shares 0 us-gaap/2025 Class Of Stock= Series B Preferred Stock;
0001437749-25-017064 20250331 Preferred Stock Shares Outstanding 0.0000 shares 0 us-gaap/2025 Class Of Stock= Series C Preferred Stock; Subsidiary Sale Of Stock= The2022 Private Placement;
0001437749-25-017064 20241231 Preferred Stock Value 6000.0000 USD 0 us-gaap/2025 Class Of Stock= Series B Preferred Stock;
0001437749-25-017064 20240331 Repayments Of Notes Payable 0.0000 USD 1 us-gaap/2025
0001437749-25-017064 20231231 Shares Outstanding 7000.0000 shares 0 us-gaap/2025 Equity Components= Preferred Stock;
0001437749-25-017064 20240331 Shares Outstanding 2000.0000 shares 0 us-gaap/2025 Equity Components= Preferred Stock;
0001437749-25-017064 20241231 Stockholders Equity 6000.0000 USD 0 us-gaap/2025 Equity Components= Preferred Stock;
0001437749-25-017064 20241231 Stockholders Equity -183457000.0000 USD 0 us-gaap/2025 Equity Components= Retained Earnings;
0001437749-25-017064 20240331 Stock Issued During Period Value Conversion Of Convertible Securities 0.0000 USD 1 us-gaap/2025 Conversion Of Stock By Unique Description= Conversion Of Series B Preferred Stock To Common Stock;
0001437749-25-017064 20240331 Stock Issued During Period Value Conversion Of Convertible Securities 226000.0000 USD 1 us-gaap/2025 Conversion Of Stock By Unique Description= Conversion Of Series B Preferred Stock To Common Stock; Equity Components= Additional Paid In Capital;
0001437749-25-017064 20240331 Stock Issued During Period Value Conversion Of Convertible Securities 233000.0000 USD 1 us-gaap/2025 Conversion Of Stock By Unique Description= Conversion Of Series C Preferred Stock To Common Stock; Equity Components= Additional Paid In Capital;
0001437749-25-017064 20220831 Stock Issued In Connection With Exercise Of Warrants Shares 1715.0000 shares 0 0001437749-25-017064 Class Of Warrant Or Right= Amended July2020 Warrants;
0001437749-25-017064 20250331 Stock Issued In Connection With Exercise Of Warrants Shares 2041814.0000 shares 1 0001437749-25-017064 Class Of Warrant Or Right= Prefunded Warrants2024 Public Offering;
0001437749-25-017064 20250331 Stock Issued In Connection With Exercise Of Warrants Value 343000.0000 USD 1 0001437749-25-017064 Class Of Warrant Or Right= Series F3 Warrants; Equity Components= Additional Paid In Capital;
0001437749-25-010730 20241231 Common Stock Shares Issued 4885000.0000 shares 0 us-gaap/2024
0001437749-25-010730 20231231 Accounts Payable Current 906000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Accrued Liabilities Current 1169000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Adjustments To Additional Paid In Capital Down Round Feature Adjustment Related To Preferred Stock 0.0000 USD 4 0001437749-25-010730 Class Of Stock= Series C Preferred Stock; Equity Components= Preferred Stock;
0001437749-25-010730 20231231 Adjustments To Additional Paid In Capital Modification Of Warrant 479000.0000 USD 4 0001437749-25-010730 Equity Components= Additional Paid In Capital;
0001437749-25-010730 20231231 Adjustments To Additional Paid In Capital Modification Of Warrant 0.0000 USD 4 0001437749-25-010730 Equity Components= Preferred Stock;
0001437749-25-010730 20241231 Adjustments To Additional Paid In Capital Modification Of Warrant 0.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= The2024 Warrant Reprice Transaction; Equity Components= Preferred Stock;
0001437749-25-010730 20241231 Adjustments To Additional Paid In Capital Modification Of Warrant -1005000.0000 USD 4 0001437749-25-010730 Equity Components= Retained Earnings;
0001437749-25-010730 20231231 Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition 291000.0000 USD 4 us-gaap/2024 Title Of Individual= Employees And Directors;
0001437749-25-010730 20241231 Amortization Of Financing Costs And Discounts 62000.0000 USD 4 us-gaap/2024 Debt Instrument= Unsecured Convertible Notes;
0001437749-25-010730 20241231 Assets Current 1935000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations 206000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20241231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect -2699000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Conversion Of Stock Amount Converted1 1023000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Cost Of Goods And Services Sold 0.0000 USD 4 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0001437749-25-010730 20231231 Down Round Feature Adjustments Related To Common Stock Warrants 0.0000 USD 4 0001437749-25-010730
0001437749-25-010730 20241231 Equity Issued During Period Value New Issues 2858000.0000 USD 4 0001437749-25-010730 Subsidiary Sale Of Stock= The2024 Public Offering;
0001437749-25-010730 20230430 Fair Value Adjustment Of Warrants -14000000.0000 USD 0 us-gaap/2024 Class Of Warrant Or Right= Amended July2020 Warrants;
0001437749-25-010730 20241231 Fair Value Adjustment Of Warrants -114000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20230930 Gains Losses On Extinguishment Of Debt 13000.0000 USD 1 us-gaap/2024 Debt Instrument= Original Issue Discount Senior Secured Convertible Debentures;
0001437749-25-010730 20231231 Income Loss From Continuing Operations Per Basic Share -110.0200 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity -124000.0000 USD 4 us-gaap/2024 Disposal Group Classification= Discontinued Operations Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Dermadoctor;
0001437749-25-010730 20241231 Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity 111000.0000 USD 4 us-gaap/2024 Disposal Group Classification= Disposal Group Heldforsale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Wound Care;
0001437749-25-010730 20241231 Increase Decrease In Accounts Payable And Accrued Liabilities 63000.0000 USD 4 us-gaap/2024 Disposal Group Classification= Discontinued Operations Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Dermadoctor;
0001437749-25-010730 20231231 Liabilities 5720000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20241231 Liabilities Of Disposal Group Including Discontinued Operation Current 0.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Modification Of Warrants 292000.0000 USD 4 0001437749-25-010730
0001437749-25-010730 20231231 Net Cash Provided By Used In Financing Activities 1910000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Net Income Loss -9640000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Net Income Loss 0.0000 USD 4 us-gaap/2024 Equity Components= Common Stock;
0001437749-25-010730 20231231 Notes Payable Current 0.0000 USD 0 us-gaap/2024
0001437749-25-010730 20241231 Payments Of Debt Issuance Costs 115000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Payments To Acquire Property Plant And Equipment 19000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Preferred Stock Shares Authorized 5000000.0000 shares 0 us-gaap/2024
0001437749-25-010730 20241231 Preferred Stock Shares Outstanding 0.0000 shares 0 us-gaap/2024 Class Of Stock= Series C Preferred Stock;
0001437749-25-010730 20231231 Prepaid Expense And Other Assets Current 256000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Proceeds From Debenture And Warrant Issuances Net 3000000.0000 USD 4 0001437749-25-010730 Debt Instrument= Convertible Notes And May2023 Warrants;
0001437749-25-010730 20241231 Proceeds From Debenture And Warrant Issuances Net 0.0000 USD 4 0001437749-25-010730 Debt Instrument= Convertible Notes And May2023 Warrants;
0001437749-25-010730 20240331 Proceeds From Divestiture Of Businesses 1100000.0000 USD 0 us-gaap/2024 Disposal Group Classification= Discontinued Operations Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Dermadoctor;
0001437749-25-010730 20241231 Proceeds From Notes Payable 500000.0000 USD 4 us-gaap/2024 Longterm Debt Type= Bridge Loan;
0001437749-25-010730 20231231 Property Plant And Equipment Net 87000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Reclassification Of Embedded Derivative Liability 169000.0000 USD 4 0001437749-25-010730 Equity Components= Additional Paid In Capital;
0001437749-25-010730 20241231 Research And Development Expense 42000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Revenue From Contract With Customer Including Assessed Tax 1377000.0000 USD 4 us-gaap/2024 Product Or Service= Neutrophase;
0001437749-25-010730 20241231 Revenue From Contract With Customer Including Assessed Tax 34000.0000 USD 4 us-gaap/2024 Product Or Service= Product And Service Other;
0001437749-25-010730 20221231 Stockholders Equity 165732000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001437749-25-010730 20231231 Stockholders Equity 3000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001437749-25-010730 20241231 Stockholders Equity Note Stock Split Conversion Ratio1 35.0000 pure 4 us-gaap/2024 Nonmonetary Transaction Type= Reverse Stock Split;
0001437749-25-010730 20231231 Stock Issued During Period Shares Conversion Of Convertible Securities 8000.0000 shares 4 us-gaap/2024 Conversion Of Stock By Unique Description= Conversion Of Series C Preferred Stock To Common Stock; Equity Components= Common Stock;
0001437749-25-010730 20231231 Stock Issued During Period Value Conversion Of Convertible Securities 293000.0000 USD 4 us-gaap/2024 Conversion Of Stock By Unique Description= Conversion Of Series B Preferred Stock To Common Stock; Equity Components= Additional Paid In Capital;
0001437749-25-010730 20241231 Stock Issued During Period Value Conversion Of Convertible Securities -268000.0000 USD 4 us-gaap/2024 Conversion Of Stock By Unique Description= Conversion Of Series B Preferred Stock To Common Stock; Equity Components= Preferred Stock;
0001437749-25-010730 20241231 Stock Issued During Period Value Reverse Stock Splits 1000.0000 USD 4 0001437749-25-010730 Equity Components= Common Stock;
0001437749-25-010730 20231231 Stock Issued In Connection With Exercise Of Warrants Value 101000.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= The2023 Warrant Reprice Transaction;
0001437749-25-010730 20241231 Stock Issued In Connection With Exercise Of Warrants Value 0.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= Prefunded Warrants2024 Public Offering; Equity Components= Retained Earnings;
0001437749-25-010730 20241231 Stock Option Plan Expense 148000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Weighted Average Number Of Shares Outstanding Basic 3396000.0000 shares 4 us-gaap/2024
0001437749-25-017064 20250331 Accounts Payable Current 800000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20240331 Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition 0.0000 USD 1 us-gaap/2025 Equity Components= Retained Earnings; Title Of Individual= Employees And Directors;
0001437749-25-017064 20250331 Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition 0.0000 USD 1 us-gaap/2025 Equity Components= Retained Earnings; Title Of Individual= Employees And Directors;
0001437749-25-017064 20240331 Amortization Of Debt Discount Premium 415000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 8944000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20250331 Derivative Liability Issued With Notes 0.0000 USD 1 0001437749-25-017064
0001437749-25-017064 20250331 Disposal Group Including Discontinued Operation Assets Noncurrent 0.0000 USD 0 us-gaap/2025
0001437749-25-017064 20250331 Fair Value Adjustment Of Warrants 0.0000 USD 1 us-gaap/2025
0001437749-25-017064 20240331 Increase Decrease In Accounts Receivable 189000.0000 USD 1 us-gaap/2025 Disposal Group Classification= Disposal Group Disposed Of By Sale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Avenova Assets;
0001437749-25-017064 20250331 Increase Decrease In Inventories -43000.0000 USD 1 us-gaap/2025 Disposal Group Classification= Disposal Group Disposed Of By Sale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Wound Care;
0001437749-25-017064 20250331 Increase Decrease In Other Operating Assets -1000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20240331 Net Income Loss 0.0000 USD 1 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017064 20250331 Net Income Loss 0.0000 USD 1 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017064 20250331 Net Income Loss 7670000.0000 USD 1 us-gaap/2025 Equity Components= Retained Earnings;
0001437749-25-017064 20240331 Operating Income Loss -2291000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20241231 Operating Lease Right Of Use Asset 955000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20240331 Payments For Repurchase Of Warrants 0.0000 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Preferred Stock Par Or Stated Value Per Share 0.0100 USD 0 us-gaap/2025
0001437749-25-017064 20250331 Preferred Stock Value 6000.0000 USD 0 us-gaap/2025 Class Of Stock= Series B Preferred Stock;
0001437749-25-017064 20240331 Stockholders Equity 9000.0000 USD 0 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017064 20250331 Stockholders Equity 6167000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20250331 Stockholders Equity 58000.0000 USD 0 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017064 20240331 Stock Issued During Period Shares Conversion Of Convertible Securities 57000.0000 shares 1 us-gaap/2025 Conversion Of Stock By Unique Description= Conversion Of Series C Preferred Stock To Common Stock; Equity Components= Common Stock;
0001437749-25-017064 20250331 Stock Issued In Connection With Exercise Of Warrants Shares 527784.0000 shares 0 0001437749-25-017064 Class Of Warrant Or Right= The July2024 Series F3 Warrants;
0001437749-25-017064 20250331 Stock Issued In Connection With Exercise Of Warrants Value 348000.0000 USD 1 0001437749-25-017064 Class Of Warrant Or Right= Series F3 Warrants;
0001437749-25-017064 20250331 Assets 9872000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20250331 Assets Current 9038000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20241231 Assets Of Disposal Group Including Discontinued Operation Current 54000.0000 USD 0 us-gaap/2025 Disposal Group Classification= Disposal Group Disposed Of By Sale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Wound Care;
0001437749-25-017064 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations 8944000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20250331 Common Stock Par Or Stated Value Per Share 0.0100 USD 0 us-gaap/2025
0001437749-25-017064 20250331 Depreciation 2000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20240331 Derivative Liability Issued With Notes 224000.0000 USD 1 0001437749-25-017064
0001437749-25-017064 20241231 Disposal Group Including Discontinued Operation Assets Noncurrent 9000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20240331 Down Round Feature Adjustments Related To Preferred Stock 380000.0000 USD 1 0001437749-25-017064
0001437749-25-017064 20240331 Fair Value Adjustment Of Warrants -194000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20240331 Increase Decrease In Accounts Receivable 108000.0000 USD 1 us-gaap/2025 Disposal Group Classification= Disposal Group Disposed Of By Sale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Wound Care;
0001437749-25-017064 20250331 Liabilities Of Disposal Group Including Discontinued Operation Current 0.0000 USD 0 us-gaap/2025
0001437749-25-017064 20240331 Net Cash Provided By Used In Investing Activities -2000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20240331 Net Income Loss 0.0000 USD 1 us-gaap/2025 Equity Components= Preferred Stock;
0001437749-25-017064 20250331 Net Income Loss 7670000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Net Income Loss 0.0000 USD 1 us-gaap/2025 Equity Components= Additional Paid In Capital;
0001437749-25-017064 20250331 Net Income Loss Available To Common Stockholders Basic 7670000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20240331 Noncash Gain On Changes In Combined Derivative Liability -65000.0000 USD 1 0001437749-25-017064
0001437749-25-017064 20250331 Notes Payable Current 0.0000 USD 0 us-gaap/2025
0001437749-25-017064 20241231 Operating Lease Liability Noncurrent 709000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20240331 Operating Lease Right Of Use Asset Amortization Expense 84000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20241231 Other Assets Noncurrent 480000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20240331 Other Nonoperating Income Expense -460000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Payments For Repurchase Of Warrants 1815000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20240331 Payments To Acquire Property Plant And Equipment 2000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20241231 Preferred Stock Shares Issued 1000.0000 shares 0 us-gaap/2025 Class Of Stock= Series B Preferred Stock;
0001437749-25-017064 20250331 Prepaid Expense And Other Assets Current 571000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20240331 Property Plant And Equipment Net 44000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20250331 Property Plant And Equipment Net 12000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20250331 Retained Earnings Accumulated Deficit -175787000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20231231 Stockholders Equity -174849000.0000 USD 0 us-gaap/2025 Equity Components= Retained Earnings;
0001437749-25-017064 20240331 Stockholders Equity 160000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20241231 Stockholders Equity -129000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20241231 Stockholders Equity 183273000.0000 USD 0 us-gaap/2025 Equity Components= Additional Paid In Capital;
0001437749-25-017064 20240331 Stock Issued During Period Value Conversion Of Convertible Securities -234000.0000 USD 1 us-gaap/2025 Conversion Of Stock By Unique Description= Conversion Of Series C Preferred Stock To Common Stock; Equity Components= Preferred Stock;
0001437749-25-017064 20240331 Weighted Average Number Of Diluted Shares Outstanding 120000.0000 shares 1 us-gaap/2025
0001437749-25-010730 20241231 General And Administrative Expense 7379000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Accounts Notes And Loans Receivable Net Current 680000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20241231 Accrued Liabilities Current 1257000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Adjustments To Additional Paid In Capital Down Round Feature Adjustment Related To Preferred Stock 0.0000 USD 4 0001437749-25-010730 Class Of Stock= Series B Preferred Stock;
0001437749-25-010730 20241231 Adjustments To Additional Paid In Capital Modification Of Warrant 0.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= The2024 Warrant Reprice Transaction; Equity Components= Common Stock;
0001437749-25-010730 20241231 Adjustments To Additional Paid In Capital Modification Of Warrant 0.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= The2024 Warrant Reprice Transaction; Equity Components= Retained Earnings;
0001437749-25-010730 20241231 Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition 0.0000 USD 4 us-gaap/2024 Equity Components= Common Stock; Title Of Individual= Employees And Directors;
0001437749-25-010730 20231231 Assets Current 7154000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Assets Of Disposal Group Including Discontinued Operation Current 2730000.0000 USD 0 us-gaap/2024 Disposal Group Classification= Discontinued Operations Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Dermadoctor;
0001437749-25-010730 20241231 Assets Of Disposal Group Including Discontinued Operation Current 0.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Disposal Group Including Discontinued Operations -373000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Commitments And Contingencies USD 0 us-gaap/2024
0001437749-25-010730 20231231 Common Stock Shares Issued 321000.0000 shares 0 us-gaap/2024
0001437749-25-010730 20241231 Cost Of Goods And Services Sold 3300000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Derivative Liability Issued With Notes 224000.0000 USD 4 0001437749-25-010730
0001437749-25-010730 20241231 Down Round Feature Adjustments Related To Preferred Stock 380000.0000 USD 4 0001437749-25-010730
0001437749-25-010730 20241231 Earnings Per Share Basic -2.5300 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity 169000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Fair Value Adjustment Of Warrants -51000.0000 USD 4 us-gaap/2024 Class Of Warrant Or Right= The December2023 Warrants; Scenario= Stockholder Approval May282024;
0001437749-25-010730 20231231 Gains Losses On Extinguishment Of Debt 0.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 General And Administrative Expense 5447000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity -3899000.0000 USD 4 us-gaap/2024 Disposal Group Classification= Discontinued Operations Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Dermadoctor;
0001437749-25-010730 20231231 Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity 404000.0000 USD 4 us-gaap/2024 Disposal Group Classification= Disposal Group Heldforsale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Wound Care;
0001437749-25-010730 20241231 Increase Decrease In Accounts Payable And Accrued Liabilities -195000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Increase Decrease In Accounts Receivable -262000.0000 USD 4 us-gaap/2024 Disposal Group Classification= Discontinued Operations Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Dermadoctor;
0001437749-25-010730 20231231 Increase Decrease In Other Operating Assets 6000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Modification Of Warrants 69000.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= The2024 Warrant Reprice Transaction;
0001437749-25-010730 20231231 Net Cash Provided By Used In Investing Activities -19000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Net Income Loss 0.0000 USD 4 us-gaap/2024 Equity Components= Common Stock;
0001437749-25-010730 20241231 Net Income Loss -7223000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Operating Lease Liability Noncurrent 1108000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Operating Lease Right Of Use Asset Amortization Expense 305000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Operating Lease Right Of Use Asset Amortization Expense 112000.0000 USD 4 us-gaap/2024 Disposal Group Classification= Discontinued Operations Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Dermadoctor;
0001437749-25-010730 20241231 Payments To Acquire Property Plant And Equipment 0.0000 USD 4 us-gaap/2024 Disposal Group Classification= Discontinued Operations Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Dermadoctor;
0001437749-25-010730 20241231 Preferred Stock Convertible Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 380000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20230430 Proceeds From Debenture And Warrant Issuances Net 3000000.0000 USD 0 0001437749-25-010730 Subsidiary Sale Of Stock= The2023 Private Placement;
0001437749-25-010730 20231231 Proceeds From Divestiture Of Businesses 0.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Proceeds From Divestiture Of Businesses 1070000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Proceeds From Issuance Or Sale Of Equity 0.0000 USD 4 us-gaap/2024 Subsidiary Sale Of Stock= Underwritten Registered Direct Offering;
0001437749-25-010730 20231231 Proceeds From Notes Payable 0.0000 USD 4 us-gaap/2024 Longterm Debt Type= Bridge Loan;
0001437749-25-010730 20231231 Proceeds From Warrant Exercises 600000.0000 USD 0 us-gaap/2024 Class Of Warrant Or Right= The2023 Warrant Reprice Transaction;
0001437749-25-010730 20231231 Retained Earnings Accumulated Deficit -174849000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Revenue From Contract With Customer Including Assessed Tax 10455000.0000 USD 4 us-gaap/2024 Product Or Service= Total Product Revenue;
0001437749-25-010730 20241231 Shares Outstanding 4885000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001437749-25-010730 20231231 Stock Issued During Period Shares Conversion Of Convertible Securities -6000.0000 shares 4 us-gaap/2024 Conversion Of Stock By Unique Description= Conversion Of Series B Preferred Stock To Common Stock; Equity Components= Preferred Stock;
0001437749-25-010730 20241231 Stock Issued During Period Shares Conversion Of Convertible Securities 205000.0000 shares 4 us-gaap/2024 Conversion Of Stock By Unique Description= Conversion Of Series C Preferred Stock To Common Stock; Equity Components= Common Stock;
0001437749-25-010730 20241231 Stock Issued During Period Shares Reverse Stock Splits 0.0000 shares 4 us-gaap/2024 Equity Components= Preferred Stock;
0001437749-25-010730 20231231 Stock Issued During Period Value Conversion Of Convertible Securities 0.0000 USD 4 us-gaap/2024 Conversion Of Stock By Unique Description= Conversion Of Series B Preferred Stock To Common Stock;
0001437749-25-010730 20231231 Stock Issued In Connection With Exercise Of Warrants Shares 0.0000 shares 4 0001437749-25-010730 Class Of Warrant Or Right= The2023 Warrant Reprice Transaction; Equity Components= Preferred Stock;
0001437749-25-010730 20241231 Stock Issued In Connection With Exercise Of Warrants Shares 0.0000 shares 4 0001437749-25-010730 Class Of Warrant Or Right= The2024 Warrant Reprice Transaction; Equity Components= Preferred Stock;
0001437749-25-010730 20231231 Stock Option Plan Expense 291000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Additional Paid In Capital 183273000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Adjustments To Additional Paid In Capital Down Round Feature Adjustment Related To Preferred Stock 0.0000 USD 4 0001437749-25-010730 Class Of Stock= Series B Preferred Stock; Equity Components= Preferred Stock;
0001437749-25-010730 20241231 Adjustments To Additional Paid In Capital Down Round Feature Adjustment Related To Preferred Stock 380000.0000 USD 4 0001437749-25-010730 Class Of Stock= Series C Preferred Stock; Equity Components= Additional Paid In Capital;
0001437749-25-010730 20241231 Adjustments To Additional Paid In Capital Down Round Feature Adjustment Related To Preferred Stock -380000.0000 USD 4 0001437749-25-010730 Class Of Stock= Series C Preferred Stock; Equity Components= Retained Earnings;
0001437749-25-010730 20231231 Adjustments To Additional Paid In Capital Modification Of Warrant 0.0000 USD 4 0001437749-25-010730 Equity Components= Common Stock;
0001437749-25-010730 20231231 Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition 0.0000 USD 4 us-gaap/2024 Equity Components= Preferred Stock; Title Of Individual= Employees And Directors;
0001437749-25-010730 20241231 Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition 148000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital; Title Of Individual= Employees And Directors;
0001437749-25-010730 20241231 Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition 0.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings; Title Of Individual= Employees And Directors;
0001437749-25-010730 20241231 Assets 3423000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations -2370000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Common Stock Par Or Stated Value Per Share 0.0100 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Common Stock Shares Outstanding 321000.0000 shares 0 us-gaap/2024
0001437749-25-010730 20241231 Conversion Of Stock Amount Converted1 1944000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Convertible Debt Current 0.0000 USD 0 us-gaap/2024
0001437749-25-010730 20241231 Derivative Liabilities Noncurrent 0.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Disposal Group Including Discontinued Operation Assets Noncurrent 19000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity 1360000.0000 USD 4 us-gaap/2024 Derivative Instrument Risk= Warrant Liability;
0001437749-25-010730 20241231 Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity 312000.0000 USD 4 us-gaap/2024 Derivative Instrument Risk= Warrant Liability;
0001437749-25-010730 20241231 Equity Issued During Period Shares And Warrants New Issues 1495000.0000 shares 4 0001437749-25-010730 Equity Components= Common Stock; Subsidiary Sale Of Stock= The2024 Public Offering;
0001437749-25-010730 20230430 Fair Value Adjustment Of Warrants -100000.0000 USD 0 us-gaap/2024 Class Of Warrant Or Right= Amended November2021 Warrants Exercisable For650;
0001437749-25-010730 20230430 Fair Value Adjustment Of Warrants 40000.0000 USD 0 us-gaap/2024 Debt Instrument= Original Issue Discount Senior Secured Convertible Debentures;
0001437749-25-010730 20240630 Fair Value Adjustment Of Warrants 7000.0000 USD 0 us-gaap/2024 Class Of Warrant Or Right= September2022 Warrants Amended;
0001437749-25-010730 20241231 Fair Value Adjustment Of Warrants 200000.0000 USD 4 us-gaap/2024 Class Of Warrant Or Right= May2023 Warrants; Scenario= Stockholder Approval June92023;
0001437749-25-010730 20241231 Fair Value Adjustment Of Warrants 70000.0000 USD 4 us-gaap/2024 Class Of Warrant Or Right= September2022 November2022 And May2023 Warrants; Scenario= Post Amendment June142024;
0001437749-25-010730 20231231 Gain Loss On Modification Of Warrants -292000.0000 USD 4 0001437749-25-010730
0001437749-25-010730 20231231 Income Loss From Continuing Operations -6145000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Increase Decrease In Other Operating Assets 2000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Inventory Net 501000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20241231 Liabilities 3552000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Net Income Loss -9640000.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001437749-25-010730 20231231 Operating Income Loss -4102000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Operating Lease Liability Current 398000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Other Nonoperating Income Expense -369000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Preferred Stock Par Or Stated Value Per Share 0.0100 USD 0 us-gaap/2024 Class Of Stock= Series B Preferred Stock;
0001437749-25-010730 20231231 Preferred Stock Shares Issued 1000.0000 shares 0 us-gaap/2024 Class Of Stock= Series C Preferred Stock;
0001437749-25-010730 20231231 Preferred Stock Value 275000.0000 USD 0 us-gaap/2024 Class Of Stock= Series B Preferred Stock;
0001437749-25-010730 20241231 Property Plant And Equipment Net 53000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Selling And Marketing Expense 4705000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20221231 Shares Outstanding 14000.0000 shares 0 us-gaap/2024 Equity Components= Preferred Stock;
0001437749-25-010730 20221231 Stockholders Equity 1000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001437749-25-010730 20231231 Stockholders Equity 1950000.0000 USD 0 us-gaap/2024 Equity Components= Preferred Stock;
0001437749-25-010730 20241231 Stockholders Equity 6000.0000 USD 0 us-gaap/2024 Equity Components= Preferred Stock;
0001437749-25-010730 20241231 Stockholders Equity -183457000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001437749-25-010730 20241231 Stock Issued During Period Shares Conversion Of Convertible Securities -5000.0000 shares 4 us-gaap/2024 Conversion Of Stock By Unique Description= Conversion Of Series B Preferred Stock To Common Stock; Equity Components= Preferred Stock;
0001437749-25-010730 20241231 Stock Issued During Period Shares Reverse Stock Splits 107000.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0001437749-25-010730 20231231 Stock Issued During Period Value Conversion Of Convertible Securities -295000.0000 USD 4 us-gaap/2024 Conversion Of Stock By Unique Description= Conversion Of Series B Preferred Stock To Common Stock; Equity Components= Preferred Stock;
0001437749-25-010730 20241231 Stock Issued During Period Value Conversion Of Convertible Securities 0.0000 USD 4 us-gaap/2024 Conversion Of Stock By Unique Description= Conversion Of Series B Preferred Stock To Common Stock;
0001437749-25-010730 20241231 Stock Issued During Period Value Conversion Of Convertible Securities 1674000.0000 USD 4 us-gaap/2024 Conversion Of Stock By Unique Description= Conversion Of Series C Preferred Stock To Common Stock; Equity Components= Additional Paid In Capital;
0001437749-25-010730 20241231 Stock Issued In Connection With Exercise Of Warrants Value 129000.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= The2024 Warrant Reprice Transaction; Equity Components= Additional Paid In Capital;
0001437749-25-010730 20231231 Weighted Average Number Of Shares Outstanding Basic 120000.0000 shares 4 us-gaap/2024
0001437749-25-017064 20241231 Accounts Payable Current 109000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20250331 Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition 0.0000 USD 1 us-gaap/2025 Equity Components= Common Stock; Title Of Individual= Employees And Directors;
0001437749-25-017064 20250331 Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition 0.0000 USD 1 us-gaap/2025 Equity Components= Preferred Stock; Title Of Individual= Employees And Directors;
0001437749-25-017064 20250331 Adjustments To Additional Paid In Capital Warrant Repurchase 1990000.0000 USD 1 0001437749-25-017064 Equity Components= Additional Paid In Capital;
0001437749-25-017064 20240331 Amortization Of Financing Costs And Discounts 433000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20240331 Amortization Of Financing Costs And Discounts 1.0000 USD 1 us-gaap/2025 Debt Instrument= Unsecured Convertible Notes;
0001437749-25-017064 20250331 Amortization Of Financing Costs And Discounts 0.0000 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Amortization Of Financing Costs And Discounts 39.0000 USD 1 us-gaap/2025 Debt Instrument= Unsecured Convertible Notes;
0001437749-25-017064 20241231 Assets Of Disposal Group Including Discontinued Operation Current 1233000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20241231 Assets Of Disposal Group Including Discontinued Operation Current 1179000.0000 USD 0 us-gaap/2025 Disposal Group Classification= Disposal Group Disposed Of By Sale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Avenova Assets;
0001437749-25-017064 20231231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 3606000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations -3032000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Commitments And Contingencies USD 0 us-gaap/2025
0001437749-25-017064 20250331 Down Round Feature Adjustments Related To Preferred Stock 0.0000 USD 1 0001437749-25-017064
0001437749-25-017064 20250331 General And Administrative Expense 2701000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity 10470000.0000 USD 1 us-gaap/2025 Disposal Group Classification= Disposal Group Disposed Of By Sale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Avenova Assets;
0001437749-25-017064 20240331 Income Loss From Discontinued Operations Net Of Tax Per Basic Share -2.4100 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Income Loss From Discontinued Operations Net Of Tax Per Basic Share 2.0700 USD 1 us-gaap/2025
0001437749-25-017064 20240331 Increase Decrease In Accounts Payable And Accrued Liabilities 63000.0000 USD 1 us-gaap/2025 Disposal Group Classification= Discontinued Operations Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Dermadoctor;
0001437749-25-017064 20240331 Increase Decrease In Inventories 114000.0000 USD 1 us-gaap/2025 Disposal Group Classification= Disposal Group Disposed Of By Sale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Avenova Assets;
0001437749-25-017064 20250331 Increase Decrease In Inventories 0.0000 USD 1 us-gaap/2025
0001437749-25-017064 20240331 Increase Decrease In Other Operating Assets 0.0000 USD 1 us-gaap/2025 Disposal Group Classification= Disposal Group Disposed Of By Sale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Avenova Assets;
0001437749-25-017064 20240331 Increase Decrease In Prepaid Deferred Expense And Other Assets 24000.0000 USD 1 us-gaap/2025 Disposal Group Classification= Disposal Group Disposed Of By Sale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Avenova Assets;
0001437749-25-017064 20250331 Liabilities And Stockholders Equity 9872000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20241231 Liabilities Of Disposal Group Including Discontinued Operation Current 1190000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20240331 Loss Income From Discontinued Operations Net Of Tax Attributable To Parent 289000.0000 USD 1 0001437749-25-017064
0001437749-25-017064 20240331 Net Cash Provided By Used In Financing Activities -597000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Net Cash Provided By Used In Financing Activities -1708000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Net Cash Provided By Used In Investing Activities 0.0000 USD 1 us-gaap/2025
0001437749-25-017064 20241231 Notes Payable Current 500000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20250331 Other Nonoperating Income Expense -40000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Payments For Repurchase Of Warrants 1800000.0000 USD 0 us-gaap/2025 Class Of Warrant Or Right= The July2024 Series F3 Warrants;
0001437749-25-017064 20250331 Payments To Acquire Property Plant And Equipment 0.0000 USD 1 us-gaap/2025
0001437749-25-017064 20241231 Preferred Stock Shares Outstanding 1000.0000 shares 0 us-gaap/2025 Class Of Stock= Series B Preferred Stock;
0001437749-25-017064 20240229 Repayments Of Convertible Debt 45000.0000 USD 0 us-gaap/2025 Debt Instrument= Original Issue Discount Senior Secured Convertible Debentures;
0001437749-25-017064 20231231 Stockholders Equity 3314000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20240331 Stockholders Equity 177109000.0000 USD 0 us-gaap/2025 Equity Components= Additional Paid In Capital;
0001437749-25-017064 20250331 Stock Issued In Connection With Exercise Of Warrants Value 0.0000 USD 1 0001437749-25-017064 Class Of Warrant Or Right= Series F2 Warrants; Equity Components= Retained Earnings;
0001437749-25-017064 20250331 Stock Issued In Connection With Exercise Of Warrants Value 0.0000 USD 1 0001437749-25-017064 Class Of Warrant Or Right= Series F3 Warrants; Equity Components= Retained Earnings;
0001437749-25-017064 20240331 Weighted Average Number Of Shares Outstanding Basic 120000.0000 shares 1 us-gaap/2025
0001437749-25-010730 20231231 Additional Paid In Capital 176210000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Adjustments To Additional Paid In Capital Down Round Feature Adjustment Related To Preferred Stock 6385000.0000 USD 4 0001437749-25-010730 Class Of Stock= Series B Preferred Stock; Equity Components= Additional Paid In Capital;
0001437749-25-010730 20231231 Adjustments To Additional Paid In Capital Down Round Feature Adjustment Related To Preferred Stock 0.0000 USD 4 0001437749-25-010730 Class Of Stock= Series B Preferred Stock; Equity Components= Common Stock;
0001437749-25-010730 20231231 Adjustments To Additional Paid In Capital Down Round Feature Adjustment Related To Preferred Stock 0.0000 USD 4 0001437749-25-010730 Class Of Stock= Series C Preferred Stock;
0001437749-25-010730 20231231 Adjustments To Additional Paid In Capital Down Round Feature Adjustment Related To Preferred Stock -672000.0000 USD 4 0001437749-25-010730 Class Of Stock= Series C Preferred Stock; Equity Components= Retained Earnings;
0001437749-25-010730 20241231 Adjustments To Additional Paid In Capital Down Round Feature Adjustment Related To Preferred Stock 0.0000 USD 4 0001437749-25-010730 Class Of Stock= Series C Preferred Stock;
0001437749-25-010730 20241231 Adjustments To Additional Paid In Capital Down Round Feature Adjustment Related To Preferred Stock 0.0000 USD 4 0001437749-25-010730 Class Of Stock= Series C Preferred Stock; Equity Components= Preferred Stock;
0001437749-25-010730 20231231 Adjustments To Additional Paid In Capital Modification Of Warrant 0.0000 USD 4 0001437749-25-010730 Equity Components= Retained Earnings;
0001437749-25-010730 20231231 Adjustments To Additional Paid In Capital Reclassifications Of Warrants 1360000.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= May2023 Warrants; Equity Components= Additional Paid In Capital;
0001437749-25-010730 20231231 Adjustments To Additional Paid In Capital Reclassifications Of Warrants 0.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= May2023 Warrants; Equity Components= Common Stock;
0001437749-25-010730 20231231 Assets Of Disposal Group Including Discontinued Operation Current 2730000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20241231 Assets Of Disposal Group Including Discontinued Operation Current 48000.0000 USD 0 us-gaap/2024 Disposal Group Classification= Disposal Group Heldforsale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Wound Care;
0001437749-25-010730 20231231 Cash Cash Equivalents And Restricted Cash Equivalents Period Increase Decrease Heldfor Sale Assets 503000.0000 USD 4 0001437749-25-010730
0001437749-25-010730 20241231 Common Stock Shares Outstanding 4885000.0000 shares 0 us-gaap/2024
0001437749-25-010730 20231231 Convertible Debt Current 1137000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Depreciation 51000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Depreciation 40000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Derivative Liabilities Noncurrent 334000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20230430 Fair Value Adjustment Of Warrants -74000.0000 USD 0 us-gaap/2024 Class Of Warrant Or Right= The Amended November2022 A1 And A2 Warrants;
0001437749-25-010730 20231231 Fair Value Adjustment Of Warrants -272000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Gain Loss On Sale Of Business 0.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Proceeds From Warrant Exercises 247000.0000 USD 4 us-gaap/2024 Class Of Warrant Or Right= Warrants And Prefunded Warrants;
0001437749-25-010730 20241231 Gains Losses On Extinguishment Of Debt -13000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Gross Profit 6084000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Income Loss From Continuing Operations -7210000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Increase Decrease In Operating Lease Liability -31000.0000 USD 4 us-gaap/2024 Disposal Group Classification= Discontinued Operations Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Dermadoctor;
0001437749-25-010730 20231231 Increase Decrease In Other Operating Assets 9000.0000 USD 4 us-gaap/2024 Disposal Group Classification= Discontinued Operations Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Dermadoctor;
0001437749-25-010730 20241231 Increase Decrease In Prepaid Deferred Expense And Other Assets 48000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Increase Decrease In Prepaid Deferred Expense And Other Assets 4000.0000 USD 4 us-gaap/2024 Disposal Group Classification= Discontinued Operations Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Dermadoctor;
0001437749-25-010730 20231231 Interest Paid Discontinued Operations 15000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Inventory Valuation Reserves Including Disposal And Discontinued Operations 218000.0000 USD 0 0001437749-25-010730
0001437749-25-010730 20241231 Net Cash Provided By Used In Investing Activities 1064000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Net Income Loss -7223000.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001437749-25-010730 20241231 Net Income Loss Available To Common Stockholders Basic -8608000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Operating Lease Right Of Use Asset Amortization Expense 0.0000 USD 4 us-gaap/2024 Disposal Group Classification= Discontinued Operations Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Dermadoctor;
0001437749-25-010730 20231231 Preferred Stock Convertible Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 7057000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Preferred Stock Shares Authorized 5000000.0000 shares 0 us-gaap/2024 Class Of Stock= Series B Preferred Stock;
0001437749-25-010730 20241231 Preferred Stock Shares Authorized 5000000.0000 shares 0 us-gaap/2024 Class Of Stock= Series B Preferred Stock;
0001437749-25-010730 20231231 Preferred Stock Shares Issued 6000.0000 shares 0 us-gaap/2024 Class Of Stock= Series B Preferred Stock;
0001437749-25-010730 20241231 Preferred Stock Value 6000.0000 USD 0 us-gaap/2024 Class Of Stock= Series B Preferred Stock;
0001437749-25-010730 20241231 Prepaid Expense And Other Assets Current 303000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20241231 Proceeds From Issuance Or Sale Of Equity 2858000.0000 USD 4 us-gaap/2024 Subsidiary Sale Of Stock= Underwritten Registered Direct Offering;
0001437749-25-010730 20231231 Proceeds From Warrant Exercises 565000.0000 USD 4 us-gaap/2024 Class Of Warrant Or Right= Warrants And Prefunded Warrants;
0001437749-25-010730 20231231 Repayments Of Convertible Debt 1474000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20240229 Repayments Of Convertible Debt 45000.0000 USD 0 us-gaap/2024 Debt Instrument= Original Issue Discount Senior Secured Convertible Debentures;
0001437749-25-010730 20231231 Revenue From Contract With Customer Including Assessed Tax 700000.0000 USD 4 us-gaap/2024 Counterparty Name= Mc Kesson Corporation; Product Or Service= Avenova Product;
0001437749-25-010730 20241231 Revenue From Contract With Customer Including Assessed Tax 1074000.0000 USD 4 us-gaap/2024 Product Or Service= Other Products;
0001437749-25-010730 20221231 Stockholders Equity 2973000.0000 USD 0 us-gaap/2024 Equity Components= Preferred Stock;
0001437749-25-010730 20231231 Stock Issued During Period Shares Conversion Of Convertible Securities 183000.0000 shares 4 us-gaap/2024 Conversion Of Stock By Unique Description= Conversion Of Series B Preferred Stock To Common Stock; Equity Components= Common Stock;
0001437749-25-010730 20231231 Stock Issued During Period Value Conversion Of Convertible Securities 2000.0000 USD 4 us-gaap/2024 Conversion Of Stock By Unique Description= Conversion Of Series B Preferred Stock To Common Stock; Equity Components= Common Stock;
0001437749-25-010730 20241231 Stock Issued During Period Value Conversion Of Convertible Securities 262000.0000 USD 4 us-gaap/2024 Conversion Of Stock By Unique Description= Conversion Of Series B Preferred Stock To Common Stock; Equity Components= Additional Paid In Capital;
0001437749-25-010730 20231231 Stock Issued In Connection With Exercise Of Warrants Shares 72000.0000 shares 4 0001437749-25-010730 Class Of Warrant Or Right= The2023 Warrant Reprice Transaction; Equity Components= Common Stock;
0001437749-25-010730 20241231 Stock Issued In Connection With Exercise Of Warrants Value 21000.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= Prefunded Warrants2024 Public Offering;
0001437749-25-010730 20241231 Stock Issued In Connection With Exercise Of Warrants Value 0.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= Prefunded Warrants2024 Public Offering; Equity Components= Additional Paid In Capital;
0001437749-25-010730 20241231 Other Nonoperating Income Expense -550000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Payments To Acquire Property Plant And Equipment 1000.0000 USD 4 us-gaap/2024 Disposal Group Classification= Discontinued Operations Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Dermadoctor;
0001437749-25-010730 20231231 Preferred Stock Par Or Stated Value Per Share 0.0100 USD 0 us-gaap/2024 Class Of Stock= Series B Preferred Stock;
0001437749-25-010730 20241231 Preferred Stock Shares Issued 1000.0000 shares 0 us-gaap/2024 Class Of Stock= Series B Preferred Stock;
0001437749-25-010730 20231231 Preferred Stock Shares Outstanding 1097.0000 shares 0 us-gaap/2024 Class Of Stock= Series C Preferred Stock; Subsidiary Sale Of Stock= The2022 Private Placement;
0001437749-25-010730 20231231 Proceeds From Warrant Exercises 200000.0000 USD 0 us-gaap/2024 Class Of Warrant Or Right= May2023 Warrants;
0001437749-25-010730 20240630 Proceeds From Warrant Exercises 200000.0000 USD 0 us-gaap/2024 Class Of Warrant Or Right= Existing Warrants;
0001437749-25-010730 20231231 Reclassification Of Embedded Derivative Liability 169000.0000 USD 4 0001437749-25-010730
0001437749-25-010730 20241231 Reclassification Of Embedded Derivative Liability 242000.0000 USD 4 0001437749-25-010730
0001437749-25-010730 20241231 Reclassification Of Embedded Derivative Liability 242000.0000 USD 4 0001437749-25-010730 Equity Components= Additional Paid In Capital;
0001437749-25-010730 20241231 Reclassify Private Placement Warrants 100000.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= March2024 Warrant;
0001437749-25-010730 20241231 Reclassify Private Placement Warrants 0.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= March2024 Warrant; Equity Components= Retained Earnings;
0001437749-25-010730 20241231 Reclassify Private Placement Warrants 0.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= The December2023 Warrants; Equity Components= Retained Earnings;
0001437749-25-010730 20241231 Revenue From Contract With Customer Including Assessed Tax 8673000.0000 USD 4 us-gaap/2024 Product Or Service= Avenova Spray;
0001437749-25-010730 20241231 Revenue From Contract With Customer Including Assessed Tax 9747000.0000 USD 4 us-gaap/2024 Product Or Service= Product;
0001437749-25-010730 20221231 Shares Outstanding 58000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001437749-25-010730 20231231 Shares Outstanding 7000.0000 shares 0 us-gaap/2024 Equity Components= Preferred Stock;
0001437749-25-010730 20241231 Shares Outstanding 1000.0000 shares 0 us-gaap/2024 Equity Components= Preferred Stock;
0001437749-25-010730 20241231 Stockholders Equity 183273000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001437749-25-010730 20231231 Stock Issued During Period Value Conversion Of Convertible Securities 0.0000 USD 4 us-gaap/2024 Conversion Of Stock By Unique Description= Conversion Of Series C Preferred Stock To Common Stock;
0001437749-25-010730 20241231 Stock Issued During Period Value Conversion Of Convertible Securities -1676000.0000 USD 4 us-gaap/2024 Conversion Of Stock By Unique Description= Conversion Of Series C Preferred Stock To Common Stock; Equity Components= Preferred Stock;
0001437749-25-010730 20241231 Stock Issued During Period Value Reverse Stock Splits -1000.0000 USD 4 0001437749-25-010730 Equity Components= Additional Paid In Capital;
0001437749-25-010730 20241231 Stock Issued In Connection With Exercise Of Warrants Shares 2042000.0000 shares 4 0001437749-25-010730 Class Of Warrant Or Right= Prefunded Warrants2024 Public Offering; Equity Components= Common Stock;
0001437749-25-010730 20241231 Stock Issued In Connection With Exercise Of Warrants Value 130000.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= The2024 Warrant Reprice Transaction;
0001437749-25-010730 20241231 Stock Issued In Connection With Exercise Of Warrants Value 0.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= The2024 Warrant Reprice Transaction; Equity Components= Preferred Stock;
0001437749-25-010730 20231231 Adjustments To Additional Paid In Capital Down Round Feature Adjustment Related To Preferred Stock -6385000.0000 USD 4 0001437749-25-010730 Class Of Stock= Series B Preferred Stock; Equity Components= Retained Earnings;
0001437749-25-010730 20231231 Adjustments To Additional Paid In Capital Down Round Feature Adjustment Related To Preferred Stock 672000.0000 USD 4 0001437749-25-010730 Class Of Stock= Series C Preferred Stock; Equity Components= Additional Paid In Capital;
0001437749-25-010730 20241231 Adjustments To Additional Paid In Capital Modification Of Warrant 1005000.0000 USD 4 0001437749-25-010730 Equity Components= Additional Paid In Capital;
0001437749-25-010730 20231231 Adjustments To Additional Paid In Capital Reclassifications Of Warrants 0.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= May2023 Warrants; Equity Components= Retained Earnings;
0001437749-25-010730 20231231 Amortization Of Financing Costs And Discounts 1694000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Assets Held For Sale Not Part Of Disposal Group Current Other 48000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 3400000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20221231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 5846000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20241231 Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity 242000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Equity Issued During Period Value New Issues 2843000.0000 USD 4 0001437749-25-010730 Equity Components= Additional Paid In Capital; Subsidiary Sale Of Stock= The2024 Public Offering;
0001437749-25-010730 20241231 Income Loss From Continuing Operations Per Basic Share -2.5300 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity -3899000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Income Loss From Discontinued Operations Net Of Tax Per Basic Share -29.1200 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Income Loss From Discontinued Operations Net Of Tax Per Basic Share 0.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Increase Decrease In Accounts Receivable -846000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Increase Decrease In Operating Lease Liability -369000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Increase Decrease In Prepaid Deferred Expense And Other Assets -11000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Increase Decrease In Prepaid Deferred Expense And Other Assets -162000.0000 USD 4 us-gaap/2024 Disposal Group Classification= Discontinued Operations Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Dermadoctor;
0001437749-25-010730 20241231 Interest Paid Discontinued Operations 0.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Interest Paid Net 147000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Liabilities And Stockholders Equity 9034000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Liabilities Of Disposal Group Including Discontinued Operation Current 698000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Net Income Loss 0.0000 USD 4 us-gaap/2024 Equity Components= Preferred Stock;
0001437749-25-010730 20241231 Net Income Loss 0.0000 USD 4 us-gaap/2024 Equity Components= Preferred Stock;
0001437749-25-010730 20231231 Noncash Expense Incurred To Obtain Consent Of Secured Note Holders 0.0000 USD 4 0001437749-25-010730
0001437749-25-010730 20231231 Noncash Gain On Changes In Combined Derivative Liability -40000.0000 USD 4 0001437749-25-010730
0001437749-25-010730 20241231 Notes Payable Current 500000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20241231 Operating Expenses 12320000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Operating Lease Right Of Use Asset 955000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Preferred Stock Shares Outstanding 1000.0000 shares 0 us-gaap/2024 Class Of Stock= Series C Preferred Stock;
0001437749-25-010730 20241231 Preferred Stock Shares Outstanding 1000.0000 shares 0 us-gaap/2024 Class Of Stock= Series B Preferred Stock;
0001437749-25-010730 20241231 Preferred Stock Shares Outstanding 131.0000 shares 0 us-gaap/2024 Class Of Stock= Series B Preferred Stock; Subsidiary Sale Of Stock= The2021 Private Placement Program;
0001437749-25-010730 20241231 Preferred Stock Shares Outstanding 0.0000 shares 0 us-gaap/2024 Class Of Stock= Series C Preferred Stock; Subsidiary Sale Of Stock= The2022 Private Placement;
0001437749-25-010730 20231231 Preferred Stock Value 1675000.0000 USD 0 us-gaap/2024 Class Of Stock= Series C Preferred Stock;
0001437749-25-010730 20241231 Reclassify Private Placement Warrants 0.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= March2024 Warrant; Equity Components= Common Stock;
0001437749-25-010730 20241231 Reclassify Private Placement Warrants 0.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= March2024 Warrant; Equity Components= Preferred Stock;
0001437749-25-010730 20241231 Reclassify Private Placement Warrants 0.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= The December2023 Warrants; Equity Components= Common Stock;
0001437749-25-010730 20241231 Reclassify Private Placement Warrants 0.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= The December2023 Warrants; Equity Components= Preferred Stock;
0001437749-25-010730 20240731 Repayments Of Convertible Debt 433000.0000 USD 0 us-gaap/2024 Debt Instrument= Original Issue Discount Senior Secured Convertible Debentures;
0001437749-25-010730 20231231 Research And Development Expense 34000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Revenue From Contract With Customer Including Assessed Tax 10455000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Shares Outstanding 321000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001437749-25-010730 20221231 Stockholders Equity 10554000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20221231 Stockholders Equity -158152000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001437749-25-010730 20231231 Stockholders Equity 176210000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001437749-25-010730 20241231 Stockholders Equity 49000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001437749-25-010730 20241231 Stock Issued During Period Shares Conversion Of Convertible Securities 625000.0000 shares 4 us-gaap/2024 Conversion Of Stock By Unique Description= Conversion Of Series B Preferred Stock To Common Stock; Equity Components= Common Stock;
0001437749-25-010730 20241231 Stock Issued During Period Value Conversion Of Convertible Securities 0.0000 USD 4 us-gaap/2024 Conversion Of Stock By Unique Description= Conversion Of Series C Preferred Stock To Common Stock; Equity Components= Retained Earnings;
0001437749-25-010730 20241231 Stock Issued During Period Value Reverse Stock Splits 0.0000 USD 4 0001437749-25-010730 Equity Components= Preferred Stock;
0001437749-25-010730 20241231 Stock Issued In Connection With Exercise Of Warrants Shares 90000.0000 shares 4 0001437749-25-010730 Class Of Warrant Or Right= The2024 Warrant Reprice Transaction; Equity Components= Common Stock;
0001437749-25-010730 20231231 Stock Issued In Connection With Exercise Of Warrants Value 0.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= The2023 Warrant Reprice Transaction; Equity Components= Common Stock;
0001437749-25-010730 20240731 Stock Issued In Connection With Exercise Of Warrants Value 20000.0000 USD 0 0001437749-25-010730 Class Of Warrant Or Right= Prefunded Warrants2024 Public Offering;
0001437749-25-010730 20241231 Stock Issued In Connection With Exercise Of Warrants Value 21000.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= Prefunded Warrants2024 Public Offering; Equity Components= Common Stock;
0001437749-25-010730 20241231 Stock Issued In Connection With Exercise Of Warrants Value 1000.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= The2024 Warrant Reprice Transaction; Equity Components= Common Stock;
0001437749-25-010730 20231231 Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 0.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Adjustments To Additional Paid In Capital Modification Of Warrant 479000.0000 USD 4 0001437749-25-010730
0001437749-25-010730 20241231 Adjustments To Additional Paid In Capital Modification Of Warrant 69000.0000 USD 4 0001437749-25-010730 Class Of Warrant Or Right= The2024 Warrant Reprice Transaction; Equity Components= Additional Paid In Capital;
0001437749-25-010730 20231231 Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition 291000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital; Title Of Individual= Employees And Directors;
0001437749-25-010730 20231231 Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition 0.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings; Title Of Individual= Employees And Directors;
0001437749-25-010730 20241231 Amortization Of Debt Discount Premium 874000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Assets Of Disposal Group Including Discontinued Operation Current 63000.0000 USD 0 us-gaap/2024 Disposal Group Classification= Disposal Group Heldforsale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Wound Care;
0001437749-25-010730 20241231 Cash And Cash Equivalents At Carrying Value 430000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20241231 Cash Cash Equivalents And Restricted Cash Equivalents Period Increase Decrease Heldfor Sale Assets 126000.0000 USD 4 0001437749-25-010730
0001437749-25-010730 20241231 Common Stock Par Or Stated Value Per Share 0.0100 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Common Stock Value 3000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20231231 Cost Of Goods And Services Sold 4371000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Cost Of Goods And Services Sold 1225000.0000 USD 4 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0001437749-25-010730 20231231 Disposal Group Including Discontinued Operation Assets Noncurrent 2749000.0000 USD 0 us-gaap/2024 Disposal Group Classification= Discontinued Operations Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Dermadoctor;
0001437749-25-010730 20231231 Down Round Feature Adjustments Related To Preferred Stock 7057000.0000 USD 4 0001437749-25-010730
0001437749-25-010730 20241231 Equity Issued During Period Value New Issues 15000.0000 USD 4 0001437749-25-010730 Equity Components= Common Stock; Subsidiary Sale Of Stock= The2024 Public Offering;
0001437749-25-010730 20241231 Fair Value Adjustment Of Warrants 200000.0000 USD 4 us-gaap/2024 Class Of Warrant Or Right= July2020 November2021 September2022 November2022 Warrants; Scenario= Postamendment;
0001437749-25-010730 20241231 Fair Value Adjustment Of Warrants 100000.0000 USD 4 us-gaap/2024 Class Of Warrant Or Right= The May2023 Warrants; Scenario= Postamendment December212023;
0001437749-25-010730 20241231 Gain Loss On Modification Of Warrants 0.0000 USD 4 0001437749-25-010730
0001437749-25-010730 20241231 Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity -124000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Increase Decrease In Accounts Payable And Accrued Liabilities -1127000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Increase Decrease In Inventories -429000.0000 USD 4 us-gaap/2024 Disposal Group Classification= Discontinued Operations Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Dermadoctor;
0001437749-25-010730 20231231 Interest Paid Net 174000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Inventory Valuation Reserves Including Disposal And Discontinued Operations 30000.0000 USD 0 0001437749-25-010730
0001437749-25-010730 20231231 Liabilities Current 4278000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20241231 Net Cash Provided By Used In Financing Activities 1500000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20231231 Net Cash Provided By Used In Operating Activities Continuing Operations -4261000.0000 USD 4 us-gaap/2024
0001437749-25-010730 20241231 Net Income Loss 0.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001437749-25-010730 20241231 Operating Lease Liability Noncurrent 709000.0000 USD 0 us-gaap/2024
0001437749-25-010730 20241231 Other Assets Noncurrent 480000.0000 USD 0 us-gaap/2024
0001437749-25-017064 20250331 Assets Of Disposal Group Including Discontinued Operation Current 0.0000 USD 0 us-gaap/2025
0001437749-25-017064 20250331 Cash And Cash Equivalents At Carrying Value 8467000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20240331 Earnings Per Share Basic -29.9500 USD 1 us-gaap/2025
0001437749-25-017064 20240331 General And Administrative Expense 2291000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20240331 Impairment Of Long Lived Assets Held For Use 0.0000 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Impairment Of Long Lived Assets Held For Use 589000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Income Loss From Continuing Operations Per Basic Share -0.6300 USD 1 us-gaap/2025
0001437749-25-017064 20240331 Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity 143000.0000 USD 1 us-gaap/2025 Disposal Group Classification= Disposal Group Disposed Of By Sale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Wound Care; Product Or Service= Product;
0001437749-25-017064 20250331 Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity 11000000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Increase Decrease In Accounts Receivable -6000.0000 USD 1 us-gaap/2025 Disposal Group Classification= Disposal Group Disposed Of By Sale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Wound Care;
0001437749-25-017064 20240331 Increase Decrease In Inventories -183000.0000 USD 1 us-gaap/2025 Disposal Group Classification= Discontinued Operations Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Dermadoctor;
0001437749-25-017064 20240331 Increase Decrease In Inventories -15000.0000 USD 1 us-gaap/2025 Disposal Group Classification= Disposal Group Disposed Of By Sale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Wound Care;
0001437749-25-017064 20240331 Increase Decrease In Operating Lease Liability -60000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Increase Decrease In Other Operating Assets -9000.0000 USD 1 us-gaap/2025 Disposal Group Classification= Disposal Group Disposed Of By Sale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Avenova Assets;
0001437749-25-017064 20240331 Increase Decrease In Prepaid Deferred Expense And Other Assets 72000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20241231 Liabilities 3552000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20241231 Liabilities Of Disposal Group Including Discontinued Operation Current 1147000.0000 USD 0 us-gaap/2025 Disposal Group Classification= Disposal Group Disposed Of By Sale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Avenova Assets;
0001437749-25-017064 20250331 Net Cash Provided By Used In Operating Activities -1324000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Noncash Expense Incurred To Obtain Consent Of Secured Note Holders 0.0000 USD 1 0001437749-25-017064
0001437749-25-017064 20250331 Operating Expenses 3290000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20241231 Operating Lease Liability Current 398000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20250331 Operating Lease Right Of Use Asset Amortization Expense 53000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20241231 Property Plant And Equipment Net 44000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20240731 Repayments Of Convertible Debt 433000.0000 USD 0 us-gaap/2025 Debt Instrument= Original Issue Discount Senior Secured Convertible Debentures;
0001437749-25-017064 20250331 Repayments Of Notes Payable 507000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20241231 Retained Earnings Accumulated Deficit -183457000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20240331 Shares Outstanding 915000.0000 shares 0 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017064 20231231 Stockholders Equity 176210000.0000 USD 0 us-gaap/2025 Equity Components= Additional Paid In Capital;
0001437749-25-017064 20240331 Stockholders Equity 1485000.0000 USD 0 us-gaap/2025 Equity Components= Preferred Stock;
0001437749-25-017064 20250331 Stockholders Equity 6000.0000 USD 0 us-gaap/2025 Equity Components= Preferred Stock;
0001437749-25-017064 20240331 Stock Issued During Period Shares Conversion Of Convertible Securities -5000.0000 shares 1 us-gaap/2025 Conversion Of Stock By Unique Description= Conversion Of Series B Preferred Stock To Common Stock; Equity Components= Preferred Stock;
0001437749-25-017064 20250131 Stock Issued In Connection With Exercise Of Warrants Shares 402727.0000 shares 0 0001437749-25-017064 Class Of Warrant Or Right= The July2024 Series F3 Warrants;
0001437749-25-017064 20250331 Stock Issued In Connection With Exercise Of Warrants Shares 403000.0000 shares 1 0001437749-25-017064 Class Of Warrant Or Right= Series F2 Warrants; Equity Components= Common Stock;
0001437749-25-017064 20250331 Stock Option Plan Expense 2000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Unsecured Debt Current 84000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20250331 Weighted Average Number Of Diluted Shares Outstanding 5415000.0000 shares 1 us-gaap/2025
0001437749-25-017064 20250331 Weighted Average Number Of Shares Outstanding Basic 5308000.0000 shares 1 us-gaap/2025
0001437749-25-017064 20241231 Additional Paid In Capital 183273000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20240331 Adjustments To Additional Paid In Capital Down Round Feature Adjustment Related To Preferred Stock 0.0000 USD 1 0001437749-25-017064 Class Of Stock= Series C Preferred Stock;
0001437749-25-017064 20240331 Amortization Of Financing Costs And Discounts 400000.0000 USD 1 us-gaap/2025 Debt Instrument= Original Issue Discount Senior Secured Convertible Debentures;
0001437749-25-017064 20241231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 907000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20241231 Common Stock Shares Authorized 150000000.0000 shares 0 us-gaap/2025
0001437749-25-017064 20240331 Conversion Of Stock Amount Converted1 465000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20240331 Earnings Per Share Diluted -29.9500 USD 1 us-gaap/2025
0001437749-25-017064 20240331 Income Loss From Continuing Operations Per Basic Share -27.5400 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Income Loss From Continuing Operations Per Diluted Share -0.6100 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity 530000.0000 USD 1 us-gaap/2025 Disposal Group Classification= Disposal Group Disposed Of By Sale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Wound Care; Product Or Service= Product;
0001437749-25-017064 20240331 Increase Decrease In Accounts Payable And Accrued Liabilities 162000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20240331 Increase Decrease In Accounts Payable And Accrued Liabilities 18000.0000 USD 1 us-gaap/2025 Disposal Group Classification= Disposal Group Disposed Of By Sale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Wound Care;
0001437749-25-017064 20250331 Increase Decrease In Accounts Payable And Accrued Liabilities -252000.0000 USD 1 us-gaap/2025 Disposal Group Classification= Disposal Group Disposed Of By Sale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Avenova Assets;
0001437749-25-017064 20240331 Increase Decrease In Other Operating Assets -1000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20240331 Increase Decrease In Other Operating Assets -15000.0000 USD 1 us-gaap/2025 Disposal Group Classification= Discontinued Operations Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Dermadoctor;
0001437749-25-017064 20240331 Increase Decrease In Prepaid Deferred Expense And Other Assets 19000.0000 USD 1 us-gaap/2025 Disposal Group Classification= Disposal Group Disposed Of By Sale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Wound Care;
0001437749-25-017064 20250331 Interest Paid Net 8000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20241231 Liabilities And Stockholders Equity 3423000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20250331 Liabilities Current 3067000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20250331 Loss Income From Discontinued Operations Net Of Tax Attributable To Parent -11000000.0000 USD 1 0001437749-25-017064
0001437749-25-017064 20240331 Operating Expenses 2291000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Operating Lease Liability Current 403000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20250331 Operating Lease Liability Noncurrent 638000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20250331 Other Nonoperating Income Expense 12000.0000 USD 1 us-gaap/2025 Disposal Group Classification= Disposal Group Disposed Of By Sale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Avenova Assets;
0001437749-25-017064 20240630 Proceeds From Warrant Exercises 200000.0000 USD 0 us-gaap/2025 Class Of Warrant Or Right= Existing Warrants;
0001437749-25-017064 20240331 Repayments Of Convertible Debt 578000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Repayments Of Convertible Debt 0.0000 USD 1 us-gaap/2025
0001437749-25-017064 20241231 Shares Outstanding 1000.0000 shares 0 us-gaap/2025 Equity Components= Preferred Stock;
0001437749-25-017064 20231231 Stockholders Equity 3000.0000 USD 0 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017064 20240331 Stockholders Equity -178443000.0000 USD 0 us-gaap/2025 Equity Components= Retained Earnings;
0001437749-25-017064 20240331 Stock Issued During Period Shares Conversion Of Convertible Securities 0.0000 shares 1 us-gaap/2025 Conversion Of Stock By Unique Description= Conversion Of Series C Preferred Stock To Common Stock; Equity Components= Preferred Stock;
0001437749-25-017064 20240331 Stock Issued During Period Value Conversion Of Convertible Securities -231000.0000 USD 1 us-gaap/2025 Conversion Of Stock By Unique Description= Conversion Of Series B Preferred Stock To Common Stock; Equity Components= Preferred Stock;
0001437749-25-017064 20240331 Stock Issued During Period Value Conversion Of Convertible Securities 0.0000 USD 1 us-gaap/2025 Conversion Of Stock By Unique Description= Conversion Of Series B Preferred Stock To Common Stock; Equity Components= Retained Earnings;
0001437749-25-017064 20240331 Stock Issued During Period Value Conversion Of Convertible Securities 1000.0000 USD 1 us-gaap/2025 Conversion Of Stock By Unique Description= Conversion Of Series C Preferred Stock To Common Stock; Equity Components= Common Stock;
0001437749-25-017064 20250331 Stock Issued In Connection With Exercise Of Warrants Value 262000.0000 USD 1 0001437749-25-017064 Class Of Warrant Or Right= Series F2 Warrants; Equity Components= Additional Paid In Capital;
0001437749-25-017064 20250331 Additional Paid In Capital 181890000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20240331 Adjustments To Additional Paid In Capital Down Round Feature Adjustment Related To Preferred Stock 0.0000 USD 1 0001437749-25-017064 Class Of Stock= Series C Preferred Stock; Equity Components= Common Stock;
0001437749-25-017064 20240331 Adjustments To Additional Paid In Capital Down Round Feature Adjustment Related To Preferred Stock 0.0000 USD 1 0001437749-25-017064 Class Of Stock= Series C Preferred Stock; Equity Components= Preferred Stock;
0001437749-25-017064 20240331 Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition 0.0000 USD 1 us-gaap/2025 Equity Components= Common Stock; Title Of Individual= Employees And Directors;
0001437749-25-017064 20240331 Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition 0.0000 USD 1 us-gaap/2025 Equity Components= Preferred Stock; Title Of Individual= Employees And Directors;
0001437749-25-017064 20250331 Amortization Of Debt Discount Premium 26000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20241231 Assets 3423000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect 8037000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20240331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations -2578000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Disposal Group Including Discontinued Operations 11069000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20241231 Common Stock Shares Issued 4885000.0000 shares 0 us-gaap/2025
0001437749-25-017064 20250331 Conversion Of Stock Amount Converted1 0.0000 USD 1 us-gaap/2025
0001437749-25-017064 20240331 Depreciation 12000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20240331 Income Loss From Continuing Operations -2925000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20240331 Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity -289000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20240331 Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity 143000.0000 USD 1 us-gaap/2025 Disposal Group Classification= Disposal Group Disposed Of By Sale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Wound Care;
0001437749-25-017064 20240331 Increase Decrease In Accounts Payable And Accrued Liabilities 128000.0000 USD 1 us-gaap/2025 Disposal Group Classification= Disposal Group Disposed Of By Sale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Avenova Assets;
0001437749-25-017064 20250331 Increase Decrease In Accounts Payable And Accrued Liabilities -38000.0000 USD 1 us-gaap/2025 Disposal Group Classification= Disposal Group Disposed Of By Sale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Wound Care;
0001437749-25-017064 20240331 Increase Decrease In Accounts Receivable -262000.0000 USD 1 us-gaap/2025 Disposal Group Classification= Discontinued Operations Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Dermadoctor;
0001437749-25-017064 20250331 Increase Decrease In Inventories -73000.0000 USD 1 us-gaap/2025 Disposal Group Classification= Disposal Group Disposed Of By Sale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Avenova Assets;
0001437749-25-017064 20240331 Increase Decrease In Operating Lease Liability -31000.0000 USD 1 us-gaap/2025 Disposal Group Classification= Discontinued Operations Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Dermadoctor;
0001437749-25-017064 20250331 Increase Decrease In Operating Lease Liability -66000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20240331 Increase Decrease In Prepaid Deferred Expense And Other Assets 4000.0000 USD 1 us-gaap/2025 Disposal Group Classification= Discontinued Operations Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Dermadoctor;
0001437749-25-017064 20250331 Increase Decrease In Prepaid Deferred Expense And Other Assets 299000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Increase Decrease In Prepaid Deferred Expense And Other Assets 0.0000 USD 1 us-gaap/2025 Disposal Group Classification= Disposal Group Disposed Of By Sale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Avenova Assets;
0001437749-25-017064 20250331 Liabilities 3705000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20241231 Liabilities Current 2843000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20240331 Net Income Loss Available To Common Stockholders Basic -3594000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Noncash Gain On Changes In Combined Derivative Liability 0.0000 USD 1 0001437749-25-017064
0001437749-25-017064 20250331 Operating Income Loss -3290000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Other Assets Noncurrent 479000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20240331 Payments Of Debt Issuance Costs 19000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20241231 Preferred Stock Par Or Stated Value Per Share 0.0100 USD 0 us-gaap/2025
0001437749-25-017064 20250331 Preferred Stock Shares Authorized 5000000.0000 shares 0 us-gaap/2025
0001437749-25-017064 20250331 Preferred Stock Shares Issued 1000.0000 shares 0 us-gaap/2025 Class Of Stock= Series B Preferred Stock;
0001437749-25-017064 20241231 Prepaid Expense And Other Assets Current 272000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20240331 Proceeds From Warrant Exercises 0.0000 USD 1 us-gaap/2025 Class Of Warrant Or Right= Warrants And Prefunded Warrants;
0001437749-25-017064 20250331 Proceeds From Warrant Exercises 614000.0000 USD 1 us-gaap/2025 Class Of Warrant Or Right= Warrants And Prefunded Warrants;
0001437749-25-017064 20231231 Shares Outstanding 321000.0000 shares 0 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017064 20250331 Shares Outstanding 1000.0000 shares 0 us-gaap/2025 Equity Components= Preferred Stock;
0001437749-25-017064 20231231 Stockholders Equity 1950000.0000 USD 0 us-gaap/2025 Equity Components= Preferred Stock;
0001437749-25-017064 20241231 Stockholders Equity 49000.0000 USD 0 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017064 20250331 Stockholders Equity 181890000.0000 USD 0 us-gaap/2025 Equity Components= Additional Paid In Capital;
0001437749-25-017064 20240331 Stock Issued During Period Shares Conversion Of Convertible Securities 537000.0000 shares 1 us-gaap/2025 Conversion Of Stock By Unique Description= Conversion Of Series B Preferred Stock To Common Stock; Equity Components= Common Stock;
0001437749-25-017064 20240331 Stock Issued During Period Value Conversion Of Convertible Securities 5000.0000 USD 1 us-gaap/2025 Conversion Of Stock By Unique Description= Conversion Of Series B Preferred Stock To Common Stock; Equity Components= Common Stock;
0001437749-25-017064 20240331 Stock Issued During Period Value Conversion Of Convertible Securities 0.0000 USD 1 us-gaap/2025 Conversion Of Stock By Unique Description= Conversion Of Series C Preferred Stock To Common Stock; Equity Components= Retained Earnings;
0001437749-25-017064 20250331 Stock Issued In Connection With Exercise Of Warrants Shares 528000.0000 shares 1 0001437749-25-017064 Class Of Warrant Or Right= Series F3 Warrants; Equity Components= Common Stock;
0001437749-25-017064 20250331 Stock Issued In Connection With Exercise Of Warrants Value 266000.0000 USD 1 0001437749-25-017064 Class Of Warrant Or Right= Series F2 Warrants;
0001437749-25-017064 20250331 Stock Issued In Connection With Exercise Of Warrants Value 4000.0000 USD 1 0001437749-25-017064 Class Of Warrant Or Right= Series F2 Warrants; Equity Components= Common Stock;
0001437749-25-017064 20250331 Stock Issued In Connection With Exercise Of Warrants Value 5000.0000 USD 1 0001437749-25-017064 Class Of Warrant Or Right= Series F3 Warrants; Equity Components= Common Stock;
0001437749-25-017064 20241231 Unsecured Debt Current 65000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20240331 Adjustments To Additional Paid In Capital Down Round Feature Adjustment Related To Preferred Stock 380000.0000 USD 1 0001437749-25-017064 Class Of Stock= Series C Preferred Stock; Equity Components= Additional Paid In Capital;
0001437749-25-017064 20240331 Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition 60000.0000 USD 1 us-gaap/2025 Title Of Individual= Employees And Directors;
0001437749-25-017064 20250331 Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition 2000.0000 USD 1 us-gaap/2025 Equity Components= Additional Paid In Capital; Title Of Individual= Employees And Directors;
0001437749-25-017064 20250331 Adjustments To Additional Paid In Capital Warrant Repurchase 0.0000 USD 1 0001437749-25-017064 Equity Components= Common Stock;
0001437749-25-017064 20240331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations 2299000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20240331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Disposal Group Including Discontinued Operations 1271000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Common Stock Shares Authorized 150000000.0000 shares 0 us-gaap/2025
0001437749-25-017064 20250331 Common Stock Shares Issued 5816000.0000 shares 0 us-gaap/2025
0001437749-25-017064 20241231 Common Stock Shares Outstanding 4885000.0000 shares 0 us-gaap/2025
0001437749-25-017064 20250331 Common Stock Shares Outstanding 5816000.0000 shares 0 us-gaap/2025
0001437749-25-017064 20241231 Common Stock Value 49000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20250331 Common Stock Value 58000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20250331 Earnings Per Share Basic 1.4400 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Operating Lease Right Of Use Asset 343000.0000 USD 0 us-gaap/2025
0001437749-25-017064 20250331 Earnings Per Share Diluted 1.4200 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Income Loss From Continuing Operations -3330000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20240331 Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity 557000.0000 USD 1 us-gaap/2025 Disposal Group Classification= Disposal Group Disposed Of By Sale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Avenova Assets;
0001437749-25-017064 20250331 Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity 530000.0000 USD 1 us-gaap/2025 Disposal Group Classification= Disposal Group Disposed Of By Sale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Wound Care;
0001437749-25-017064 20250331 Income Loss From Discontinued Operations Net Of Tax Per Diluted Share 2.0300 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Increase Decrease In Accounts Payable And Accrued Liabilities 1698000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20240331 Increase Decrease In Accounts Receivable -243000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Increase Decrease In Accounts Receivable 0.0000 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Increase Decrease In Accounts Receivable 72000.0000 USD 1 us-gaap/2025 Disposal Group Classification= Disposal Group Disposed Of By Sale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Avenova Assets;
0001437749-25-017064 20240331 Increase Decrease In Inventories 8000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20250331 Increase Decrease In Prepaid Deferred Expense And Other Assets 0.0000 USD 1 us-gaap/2025 Disposal Group Classification= Disposal Group Disposed Of By Sale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Wound Care;
0001437749-25-017064 20240331 Interest Paid Net 236000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20241231 Liabilities Of Disposal Group Including Discontinued Operation Current 43000.0000 USD 0 us-gaap/2025 Disposal Group Classification= Disposal Group Disposed Of By Sale Not Discontinued Operations; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Wound Care;
0001437749-25-017064 20240331 Net Cash Provided By Used In Operating Activities -1979000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20240331 Net Income Loss -3214000.0000 USD 1 us-gaap/2025
0001437749-25-017064 20240331 Net Income Loss 0.0000 USD 1 us-gaap/2025 Equity Components= Additional Paid In Capital;
0001437749-25-017064 20250331 Preferred Stock Convertible Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 0.0000 USD 1 us-gaap/2025
0001437749-25-017064 20241231 Preferred Stock Shares Authorized 5000000.0000 shares 0 us-gaap/2025
0001437749-25-017064 20250331 Preferred Stock Shares Outstanding 131.0000 shares 0 us-gaap/2025 Class Of Stock= Series B Preferred Stock; Subsidiary Sale Of Stock= The2021 Private Placement Program;
0001437749-25-017064 20241231 Shares Outstanding 4885000.0000 shares 0 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017064 20250331 Shares Outstanding 5816000.0000 shares 0 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017064 20250331 Stockholders Equity -175787000.0000 USD 0 us-gaap/2025 Equity Components= Retained Earnings;
0001437749-25-017064 20240331 Stock Issued During Period Value Conversion Of Convertible Securities 0.0000 USD 1 us-gaap/2025 Conversion Of Stock By Unique Description= Conversion Of Series C Preferred Stock To Common Stock;
0001437749-25-017064 20240731 Stock Issued In Connection With Exercise Of Warrants Value 20000.0000 USD 0 0001437749-25-017064 Class Of Warrant Or Right= Prefunded Warrants2024 Public Offering;
0001437749-25-017064 20240331 Stock Option Plan Expense 60000.0000 USD 1 us-gaap/2025

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
ddate The end date for the data value, rounded to the nearest month end.
qtrs The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value.
uom The unit of measure for the value.
segments Tags used to represent axis and member reporting.
coreg If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity.
value The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point.
footnote The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank.

Tags

tag version custom abstract datatype iord crdr tlabel doc
Increase Decrease In Accounts Receivable us-gaap/2024 0 0 monetary D C Increase (Decrease) in Accounts Receivable The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
Modification Of Warrants 0001437749-25-010730 1 0 monetary D D Modification of common stock warrants, included in Other expense The amount of noncash expense from modification of warrants.
Operating Lease Liability Noncurrent us-gaap/2025 0 0 monetary I C Operating Lease, Liability, Noncurrent Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
Amortization Of Debt Discount Premium us-gaap/2024 0 0 monetary D D Amortization of Debt Discount (Premium) Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
Assets Current us-gaap/2024 0 0 monetary I D Assets, Current Amount of asset recognized for present right to economic benefit, classified as current.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 0 0 monetary I D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Operating Lease Liability Current us-gaap/2024 0 0 monetary I C Operating Lease, Liability, Current Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
Net Cash Provided By Used In Investing Activities us-gaap/2025 0 0 monetary D D Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.
Allowance For Doubtful Accounts Receivable Current us-gaap/2024 0 0 monetary I C Accounts Receivable, Allowance for Credit Loss, Current Amount of allowance for credit loss on accounts receivable, classified as current.
Assets Held For Sale Not Part Of Disposal Group Current Other us-gaap/2024 0 0 monetary I D Asset, Held-for-Sale, Not Part of Disposal Group, Other, Current Amount of other assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.
Conversion Of Stock Amount Converted1 us-gaap/2024 0 0 monetary D D Conversion of Stock, Amount Converted The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
Gain Loss On Sale Of Business us-gaap/2024 0 0 monetary D C Gain (Loss) on Disposition of Business Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.
Payments To Acquire Property Plant And Equipment us-gaap/2024 0 0 monetary D C Payments to Acquire Property, Plant, and Equipment The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
Proceeds From Issuance Or Sale Of Equity us-gaap/2024 0 0 monetary D D Proceeds from Issuance or Sale of Equity The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
Cash And Cash Equivalents At Carrying Value us-gaap/2025 0 0 monetary I D Cash and Cash Equivalent Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.
Common Stock Shares Authorized us-gaap/2025 0 0 shares I Common Stock, Shares Authorized The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations us-gaap/2025 0 0 monetary D D Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect, Continuing Operation Amount of increase (decrease) in cash, cash equivalent, and cash and cash equivalent restricted to withdrawal or usage, including effect from exchange rate change; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.
Earnings Per Share Diluted us-gaap/2025 0 0 perShare D Earnings Per Share, Diluted The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
Liabilities Of Disposal Group Including Discontinued Operation Current us-gaap/2025 0 0 monetary I C Disposal Group, Including Discontinued Operation, Liabilities, Current Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
Net Income Loss us-gaap/2024 0 0 monetary D C Net Income (Loss) Attributable to Parent The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Liabilities us-gaap/2024 0 0 monetary I C Liabilities Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.
Liabilities And Stockholders Equity us-gaap/2024 0 0 monetary I C Liabilities and Equity Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Liabilities Of Disposal Group Including Discontinued Operation Current us-gaap/2024 0 0 monetary I C Disposal Group, Including Discontinued Operation, Liabilities, Current Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
Repayments Of Convertible Debt us-gaap/2024 0 0 monetary D C Repayments of Convertible Debt The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
Retained Earnings Accumulated Deficit us-gaap/2024 0 0 monetary I C Retained Earnings (Accumulated Deficit) Amount of accumulated undistributed earnings (deficit).
Property Plant And Equipment Net us-gaap/2025 0 0 monetary I D Property, Plant and Equipment, Net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2025 0 0 monetary D D Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.
General And Administrative Expense us-gaap/2025 0 0 monetary D D General and Administrative Expense The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
Commitments And Contingencies us-gaap/2025 0 0 monetary I C Commitments and Contingencies Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
Disposal Group Including Discontinued Operation Assets Noncurrent us-gaap/2025 0 0 monetary I D Disposal Group, Including Discontinued Operation, Assets, Noncurrent Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.
Increase Decrease In Operating Lease Liability us-gaap/2025 0 0 monetary D D Increase (Decrease) in Operating Lease Liability Amount of increase (decrease) in obligation for operating lease.
Noncash Gain On Changes In Combined Derivative Liability 0001437749-25-017064 1 0 monetary D D Non-cash gain on changes in fair value of embedded derivative liability The amount of gain on changes in combined derivative liability.
Down Round Feature Adjustments Related To Preferred Stock 0001437749-25-017064 1 0 monetary D D Down round feature adjustments related to preferred stock Represents Down Round Feature Adjustments Related to Preferred Stock.
Adjustments To Additional Paid In Capital Down Round Feature Adjustment Related To Preferred Stock 0001437749-25-017064 1 0 monetary D C Adjustment of Preferred Stock conversion price Amount of decrease in additional paid in capital (APIC) resulting from down round feature adjustment related to preferred stock.
Additional Paid In Capital us-gaap/2024 0 0 monetary I C Additional Paid in Capital Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.
Common Stock Par Or Stated Value Per Share us-gaap/2024 0 0 perShare I Common Stock, Par or Stated Value Per Share Face amount or stated value per share of common stock.
Common Stock Shares Outstanding us-gaap/2024 0 0 shares I Common Stock, Shares, Outstanding Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
Convertible Debt Current us-gaap/2024 0 0 monetary I C Convertible Debt, Current The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
Payments Of Debt Issuance Costs us-gaap/2024 0 0 monetary D C Payments of Debt Issuance Costs The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.
Stockholders Equity us-gaap/2024 0 0 monetary I C Equity, Attributable to Parent Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
Stock Issued During Period Value Conversion Of Convertible Securities us-gaap/2024 0 0 monetary D C Stock Issued During Period, Value, Conversion of Convertible Securities The gross value of stock issued during the period upon the conversion of convertible securities.
Additional Paid In Capital us-gaap/2025 0 0 monetary I C Additional Paid in Capital Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.
Amortization Of Debt Discount Premium us-gaap/2025 0 0 monetary D D Amortization of Debt Discount (Premium) Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
Common Stock Shares Issued us-gaap/2025 0 0 shares I Common Stock, Shares, Issued Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
Income Loss From Continuing Operations Per Basic Share us-gaap/2025 0 0 perShare D Income (Loss) from Continuing Operations, Per Basic Share The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.
Income Loss From Discontinued Operations Net Of Tax Per Diluted Share us-gaap/2025 0 0 perShare D Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.
Income Loss From Heldfor Sale Assets 0001437749-25-010730 1 0 monetary D C Net income from held-for-sale assets (Note 22) Amount of income (loss) from held-for-sale assets.
Assets us-gaap/2024 0 0 monetary I D Assets Amount of asset recognized for present right to economic benefit.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations us-gaap/2024 0 0 monetary I D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Common Stock Shares Issued us-gaap/2024 0 0 shares I Common Stock, Shares, Issued Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
Cost Of Goods And Services Sold us-gaap/2024 0 0 monetary D D Cost of Goods and Services Sold The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
Gross Profit us-gaap/2024 0 0 monetary D C Gross Profit Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
Net Cash Provided By Used In Operating Activities Continuing Operations us-gaap/2024 0 0 monetary D Net Cash Provided by (Used in) Operating Activities, Continuing Operations Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Operating Lease Right Of Use Asset us-gaap/2024 0 0 monetary I D Operating Lease, Right-of-Use Asset Amount of lessee's right to use underlying asset under operating lease.
Other Assets Noncurrent us-gaap/2024 0 0 monetary I D Other Assets, Noncurrent Amount of noncurrent assets classified as other.
Proceeds From Notes Payable us-gaap/2024 0 0 monetary D D Proceeds from Notes Payable The cash inflow from a borrowing supported by a written promise to pay an obligation.
Loss Income From Discontinued Operations Net Of Tax Attributable To Parent 0001437749-25-017064 1 0 monetary D D nby_LossIncomeFromDiscontinuedOperationsNetOfTaxAttributableToParent Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.
Selling And Marketing Expense us-gaap/2024 0 0 monetary D D Selling and Marketing Expense The aggregate total amount of expenses directly related to the marketing or selling of products or services.
Stock Issued During Period Shares Conversion Of Convertible Securities us-gaap/2024 0 0 shares D Stock Issued During Period, Shares, Conversion of Convertible Securities Number of shares issued during the period as a result of the conversion of convertible securities.
Stock Issued During Period Shares Reverse Stock Splits us-gaap/2024 0 0 shares D Stock Issued During Period, Shares, Reverse Stock Splits Reduction in the number of shares during the period as a result of a reverse stock split.
Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount us-gaap/2024 0 0 monetary D D Warrant, Down Round Feature, Decrease in Net Income to Common Shareholder, Amount Amount of decrease in net income available to common shareholder for down round feature triggered for warrant classified as equity.
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition us-gaap/2025 0 0 monetary D C APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.
Operating Expenses us-gaap/2025 0 0 monetary D D Operating Expenses Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
Unsecured Debt Current us-gaap/2025 0 0 monetary I C Unsecured Debt, Current Carrying value as of the balance sheet date of the portion of long-term, uncollateralized debt obligations due within one year or the normal operating cycle, if longer.
Adjustments To Additional Paid In Capital Modification Of Warrant 0001437749-25-010730 1 0 monetary D C Modification of common stock warrants Amount of increase to APIC from modification of warrant.
Reclassify Private Placement Warrants 0001437749-25-010730 1 0 monetary D C Reclassification of Warrants from liability Represents the amount of reclassification of private placement warrants.
Stock Issued In Connection With Exercise Of Warrants Value 0001437749-25-010730 1 0 monetary D C Issuance of common stock in connection with Warrant Reprice Transaction, net Value of stock issued as a result of warrants exercise..
Stock Issued In Connection With Exercise Of Warrants Shares 0001437749-25-017064 1 0 shares D nby_StockIssuedInConnectionWithExerciseOfWarrantsShares Stock issued in connection with warrants exercise.
Preferred Stock Convertible Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount us-gaap/2024 0 0 monetary D D Preferred Stock, Convertible, Down Round Feature, Decrease in Net Income to Common Shareholder, Amount Amount of decrease in net income available to common shareholder for down round feature triggered for convertible preferred stock.
Accrued Liabilities Current us-gaap/2024 0 0 monetary I C Accrued Liabilities, Current Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Derivative Liabilities Noncurrent us-gaap/2024 0 0 monetary I C Derivative Liability, Noncurrent Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
Increase Decrease In Other Operating Assets us-gaap/2024 0 0 monetary D C Increase (Decrease) in Other Operating Assets Amount of increase (decrease) in operating assets classified as other.
Liabilities Current us-gaap/2024 0 0 monetary I C Liabilities, Current Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
Preferred Stock Shares Issued us-gaap/2024 0 0 shares I Preferred Stock, Shares Issued Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.
Operating Income Loss us-gaap/2025 0 0 monetary D C Operating Income (Loss) The net result for the period of deducting operating expenses from operating revenues.
Weighted Average Number Of Shares Outstanding Basic us-gaap/2025 0 0 shares D Weighted Average Number of Shares Outstanding, Basic Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Depreciation us-gaap/2025 0 0 monetary D D Depreciation The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Income Loss From Discontinued Operations Net Of Tax Per Basic Share us-gaap/2025 0 0 perShare D Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.
Operating Lease Liability Current us-gaap/2025 0 0 monetary I C Operating Lease, Liability, Current Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
Operating Lease Right Of Use Asset us-gaap/2025 0 0 monetary I D Operating Lease, Right-of-Use Asset Amount of lessee's right to use underlying asset under operating lease.
Payments For Repurchase Of Warrants us-gaap/2025 0 0 monetary D C Payments for Repurchase of Warrants The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.
Preferred Stock Par Or Stated Value Per Share us-gaap/2025 0 0 perShare I Preferred Stock, Par or Stated Value Per Share Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
Repayments Of Notes Payable us-gaap/2025 0 0 monetary D C Repayments of Notes Payable The cash outflow for a borrowing supported by a written promise to pay an obligation.
Stock Issued During Period Shares Conversion Of Convertible Securities us-gaap/2025 0 0 shares D Stock Issued During Period, Shares, Conversion of Convertible Securities Number of shares issued during the period as a result of the conversion of convertible securities.
Adjustments To Additional Paid In Capital Down Round Feature Adjustment Related To Preferred Stock 0001437749-25-010730 1 0 monetary D C Adjustment of Preferred Stock conversion price Amount of decrease in additional paid in capital (APIC) resulting from down round feature adjustment related to preferred stock.
Equity Issued During Period Shares And Warrants New Issues 0001437749-25-010730 1 0 shares D Issuance of common stock and pre-funded warrants in the 2024 Public Offering, net of issuance cost (in shares) Number of new stock and warrants issued during the period.
Amortization Of Financing Costs And Discounts us-gaap/2024 0 0 monetary D D Amortization of Debt Issuance Costs and Discounts Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.
Derivative Liability Issued With Notes 0001437749-25-017064 1 0 monetary D C Issuance of derivative liability in conjunction with Unsecured Convertible Notes Amount of derivative liability issued with notes.
Cash And Cash Equivalents At Carrying Value us-gaap/2024 0 0 monetary I D Cash and Cash Equivalents, at Carrying Value Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations us-gaap/2024 0 0 monetary D D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Continuing Operations Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from change in exchange rate. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalents include, but are not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.
Increase Decrease In Inventories us-gaap/2024 0 0 monetary D C Increase (Decrease) in Inventories The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
Interest Paid Discontinued Operations us-gaap/2024 0 0 monetary D C Interest Paid, Discontinued Operations The amount of cash paid during the current period for interest owed on debt associated with discontinued operations.
Preferred Stock Value us-gaap/2024 0 0 monetary I C Preferred Stock, Value, Issued Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
Accrued Liabilities Current us-gaap/2025 0 0 monetary I C Accrued Liabilities, Current Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Earnings Per Share Basic us-gaap/2025 0 0 perShare D Earnings Per Share, Basic The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
Increase Decrease In Other Operating Assets us-gaap/2025 0 0 monetary D C Increase (Decrease) in Other Operating Assets Amount of increase (decrease) in operating assets classified as other.
Payments To Acquire Property Plant And Equipment us-gaap/2025 0 0 monetary D C Payments to Acquire Property, Plant, and Equipment The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
Shares Outstanding us-gaap/2025 0 0 shares I Shares, Outstanding Number of shares issued which are neither cancelled nor held in the treasury.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Disposal Group Including Discontinued Operations us-gaap/2025 0 0 monetary D D Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect, Discontinued Operation Amount of increase (decrease) in cash, cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change; attributable to discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.
Fair Value Adjustment Of Warrants us-gaap/2025 0 0 monetary D D Fair Value Adjustment of Warrants Amount of expense (income) related to adjustment to fair value of warrant liability.
Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity us-gaap/2025 0 0 monetary D C Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.
Increase Decrease In Prepaid Deferred Expense And Other Assets us-gaap/2025 0 0 monetary D C Increase (Decrease) in Prepaid Expense and Other Assets Amount of increase (decrease) in prepaid expenses, and assets classified as other.
Operating Lease Right Of Use Asset Amortization Expense us-gaap/2025 0 0 monetary D D Operating Lease, Right-of-Use Asset, Periodic Reduction Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.
Preferred Stock Shares Issued us-gaap/2025 0 0 shares I Preferred Stock, Shares Issued Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.
Down Round Feature Adjustments Related To Preferred Stock 0001437749-25-010730 1 0 monetary D D Down round feature adjustments related to preferred stock Represents Down Round Feature Adjustments Related to Preferred Stock.
Noncash Expense Incurred To Obtain Consent Of Secured Note Holders 0001437749-25-010730 1 0 monetary D D Non-cash expense incurred to obtain consent of Secured Convertible Note holders Amount of noncash expense incurred to obtain consent of secured note holders.
Stock Issued In Connection With Exercise Of Warrants Shares 0001437749-25-010730 1 0 shares D Issuance of common stock in connection with Warrant Reprice Transaction, net (in shares) Stock issued in connection with warrants exercise.
Increase Decrease In Prepaid Deferred Expense And Other Assets us-gaap/2024 0 0 monetary D C Increase (Decrease) in Prepaid Expense and Other Assets Amount of increase (decrease) in prepaid expenses, and assets classified as other.
Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity us-gaap/2024 0 0 monetary D C Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity The amount of the liability for the conversion option reclassified to stockholders' equity when the embedded option no longer required separation from the host instrument.
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition us-gaap/2024 0 0 monetary D C APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.
Assets Of Disposal Group Including Discontinued Operation Current us-gaap/2024 0 0 monetary I D Disposal Group, Including Discontinued Operation, Assets, Current Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
Notes Payable Current us-gaap/2024 0 0 monetary I C Notes Payable, Current Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
Operating Expenses us-gaap/2024 0 0 monetary D D Operating Expenses Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
Operating Income Loss us-gaap/2024 0 0 monetary D C Operating Income (Loss) The net result for the period of deducting operating expenses from operating revenues.
Prepaid Expense And Other Assets Current us-gaap/2024 0 0 monetary I D Prepaid Expense and Other Assets, Current Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
Stockholders Equity Note Stock Split Conversion Ratio1 us-gaap/2024 0 0 pure D Stockholders' Equity Note, Stock Split, Conversion Ratio Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.
Increase Decrease In Inventories us-gaap/2025 0 0 monetary D C Increase (Decrease) in Inventories The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
Liabilities Current us-gaap/2025 0 0 monetary I C Liabilities, Current Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
Net Cash Provided By Used In Financing Activities us-gaap/2025 0 0 monetary D D Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.
Common Stock Shares Outstanding us-gaap/2025 0 0 shares I Common Stock, Shares, Outstanding Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
Income Loss From Continuing Operations Per Diluted Share us-gaap/2025 0 0 perShare D Income (Loss) from Continuing Operations, Per Diluted Share The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
Notes Payable Current us-gaap/2025 0 0 monetary I C Notes Payable, Current Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
Other Assets Noncurrent us-gaap/2025 0 0 monetary I D Other Assets, Noncurrent Amount of noncurrent assets classified as other.
Proceeds From Warrant Exercises us-gaap/2025 0 0 monetary D D Proceeds from Warrant Exercises The cash inflow associated with the amount received from holders exercising their stock warrants.
Down Round Feature Adjustments Related To Common Stock Warrants 0001437749-25-010730 1 0 monetary D C Down round feature adjustments related to common stock warrants The amount of down round feature adjustments related to common stock warrants.
Inventory Valuation Reserves Including Disposal And Discontinued Operations 0001437749-25-010730 1 0 monetary I C Inventory, allowance Amount of valuation reserve for inventory, including disposal group and discontinued operations.
Noncash Gain On Changes In Combined Derivative Liability 0001437749-25-010730 1 0 monetary D D Non-cash loss (gain) on changes in fair value of embedded derivative liability The amount of gain on changes in combined derivative liability.
Stock Option Plan Expense us-gaap/2024 0 0 monetary D D Stock or Unit Option Plan Expense Amount of noncash expense for option under share-based payment arrangement.
Payments Of Debt Issuance Costs us-gaap/2025 0 0 monetary D C Payments of Debt Issuance Costs The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.
Adjustments To Additional Paid In Capital Warrant Repurchase 0001437749-25-017064 1 0 monetary D C nby_AdjustmentsToAdditionalPaidInCapitalWarrantRepurchase Amount of additional paid in capital of warrants repurchased.
Noncash Expense Incurred To Obtain Consent Of Secured Note Holders 0001437749-25-017064 1 0 monetary D D Non-cash expense incurred to obtain consent of Secured Convertible Note holders Amount of noncash expense incurred to obtain consent of secured note holders.
Common Stock Value us-gaap/2024 0 0 monetary I C Common Stock, Value, Issued Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
General And Administrative Expense us-gaap/2024 0 0 monetary D D General and Administrative Expense The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
Income Loss From Continuing Operations Per Basic Share us-gaap/2024 0 0 perShare D Income (Loss) from Continuing Operations, Per Basic Share The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.
Proceeds From Divestiture Of Businesses us-gaap/2024 0 0 monetary D D Proceeds from Divestiture of Businesses The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.
Inventory Net us-gaap/2024 0 0 monetary I D Inventory, Net Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
Research And Development Expense us-gaap/2024 0 0 monetary D D Research and Development Expense Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.
Assets us-gaap/2025 0 0 monetary I D Assets Amount of asset recognized for present right to economic benefit.
Increase Decrease In Accounts Receivable us-gaap/2025 0 0 monetary D C Increase (Decrease) in Accounts Receivable The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
Liabilities And Stockholders Equity us-gaap/2025 0 0 monetary I C Liabilities and Equity Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Net Income Loss us-gaap/2025 0 0 monetary D C Net Income (Loss) Attributable to Parent The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Other Nonoperating Income Expense us-gaap/2025 0 0 monetary D C Other Nonoperating Income (Expense) Amount of income (expense) related to nonoperating activities, classified as other.
Impairment Of Long Lived Assets Held For Use us-gaap/2025 0 0 monetary D D Impairment, Long-Lived Asset, Held-for-Use The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).
Prepaid Expense And Other Assets Current us-gaap/2025 0 0 monetary I D Prepaid Expense and Other Assets, Current Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
Stockholders Equity us-gaap/2025 0 0 monetary I C Equity, Attributable to Parent Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
Common Stock Par Or Stated Value Per Share us-gaap/2025 0 0 perShare I Common Stock, Par or Stated Value Per Share Face amount or stated value per share of common stock.
Gain Loss On Modification Of Warrants 0001437749-25-010730 1 0 monetary D C Non-cash loss on modification of common stock warrants Amount of gain (loss) on modification of warrants.
Accounts Payable Current us-gaap/2024 0 0 monetary I C Accounts Payable, Current Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Stock Issued In Connection With Exercise Of Warrants Value 0001437749-25-017064 1 0 monetary D C nby_StockIssuedInConnectionWithExerciseOfWarrantsValue Value of stock issued as a result of warrants exercise..
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2024 0 0 monetary D D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Commitments And Contingencies us-gaap/2024 0 0 monetary I C Commitments and Contingencies Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
Common Stock Shares Authorized us-gaap/2024 0 0 shares I Common Stock, Shares Authorized The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Gains Losses On Extinguishment Of Debt us-gaap/2024 0 0 monetary D C Gain (Loss) on Extinguishment of Debt Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
Fair Value Adjustment Of Warrants us-gaap/2024 0 0 monetary D D Fair Value Adjustment of Warrants Amount of expense (income) related to adjustment to fair value of warrant liability.
Income Loss From Continuing Operations us-gaap/2024 0 0 monetary D C Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Amount after tax of income (loss) from continuing operations attributable to the parent.
Income Loss From Discontinued Operations Net Of Tax Per Basic Share us-gaap/2024 0 0 perShare D Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.
Increase Decrease In Operating Lease Liability us-gaap/2024 0 0 monetary D D Increase (Decrease) in Operating Lease Liability Amount of increase (decrease) in obligation for operating lease.
Interest Paid Net us-gaap/2024 0 0 monetary D C Interest Paid, Excluding Capitalized Interest, Operating Activities Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
Net Cash Provided By Used In Financing Activities us-gaap/2024 0 0 monetary D D Net Cash Provided by (Used in) Financing Activities Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Net Income Loss Available To Common Stockholders Basic us-gaap/2024 0 0 monetary D C Net Income (Loss) Available to Common Stockholders, Basic Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
Operating Lease Right Of Use Asset Amortization Expense us-gaap/2024 0 0 monetary D D Operating Lease, Right-of-Use Asset, Periodic Reduction Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.
Preferred Stock Par Or Stated Value Per Share us-gaap/2024 0 0 perShare I Preferred Stock, Par or Stated Value Per Share Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
Shares Outstanding us-gaap/2024 0 0 shares I Shares, Outstanding Number of shares issued which are neither cancelled nor held in the treasury.
Unsecured Debt Current us-gaap/2024 0 0 monetary I C Unsecured Debt, Current Carrying value as of the balance sheet date of the portion of long-term, uncollateralized debt obligations due within one year or the normal operating cycle, if longer.
Assets Current us-gaap/2025 0 0 monetary I D Assets, Current Amount of asset recognized for present right to economic benefit, classified as current.
Increase Decrease In Accounts Payable And Accrued Liabilities us-gaap/2025 0 0 monetary D D Increase (Decrease) in Accounts Payable and Accrued Liabilities The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
Liabilities us-gaap/2025 0 0 monetary I C Liabilities Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.
Amortization Of Financing Costs And Discounts us-gaap/2025 0 0 monetary D D Amortization of Debt Issuance Costs and Discounts Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.
Assets Of Disposal Group Including Discontinued Operation Current us-gaap/2025 0 0 monetary I D Disposal Group, Including Discontinued Operation, Assets, Current Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations us-gaap/2025 0 0 monetary I D Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Discontinued Operation Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.
Interest Paid Net us-gaap/2025 0 0 monetary D C Interest Paid, Excluding Capitalized Interest, Operating Activity Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
Preferred Stock Convertible Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount us-gaap/2025 0 0 monetary D D Preferred Stock, Convertible, Down Round Feature, Decrease in Net Income to Common Shareholder, Amount Amount of decrease in net income available to common shareholder for down round feature triggered for convertible preferred stock.
Preferred Stock Shares Authorized us-gaap/2025 0 0 shares I Preferred Stock, Shares Authorized The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
Preferred Stock Shares Outstanding us-gaap/2025 0 0 shares I Preferred Stock, Shares Outstanding Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
Weighted Average Number Of Diluted Shares Outstanding us-gaap/2025 0 0 shares D Weighted Average Number of Shares Outstanding, Diluted The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Adjustments To Additional Paid In Capital Reclassifications Of Warrants 0001437749-25-010730 1 0 monetary D C Reclassification of May 2023 Warrants The amount of adjustments to additional paid in capital from the reclassification of warrants.
Equity Issued During Period Value New Issues 0001437749-25-010730 1 0 monetary D C Issuance of common stock and pre-funded warrants in the 2024 Public Offering, net of issuance cost Equity impact of the value of new stock and warrants issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
Stock Issued During Period Value Reverse Stock Splits 0001437749-25-010730 1 0 monetary D C Shares issued for 35:1 reverse stock split due to rounding feature Represents the amount as a result of a reduction in the number of shares during the period as a result of a reverse stock split.
Accounts Payable Current us-gaap/2025 0 0 monetary I C Accounts Payable, Current Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations us-gaap/2024 0 0 monetary I D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Depreciation us-gaap/2024 0 0 monetary D D Depreciation The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Disposal Group Including Discontinued Operation Assets Noncurrent us-gaap/2024 0 0 monetary I D Disposal Group, Including Discontinued Operation, Assets, Noncurrent Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.
Earnings Per Share Basic us-gaap/2024 0 0 perShare D Earnings Per Share, Basic The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
Increase Decrease In Accounts Payable And Accrued Liabilities us-gaap/2024 0 0 monetary D D Increase (Decrease) in Accounts Payable and Accrued Liabilities The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
Net Cash Provided By Used In Investing Activities us-gaap/2024 0 0 monetary D D Net Cash Provided by (Used in) Investing Activities Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
Other Nonoperating Income Expense us-gaap/2024 0 0 monetary D C Other Nonoperating Income (Expense) Amount of income (expense) related to nonoperating activities, classified as other.
Preferred Stock Shares Authorized us-gaap/2024 0 0 shares I Preferred Stock, Shares Authorized The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
Preferred Stock Shares Outstanding us-gaap/2024 0 0 shares I Preferred Stock, Shares Outstanding Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
Revenue From Contract With Customer Including Assessed Tax us-gaap/2024 0 0 monetary D C Revenue from Contract with Customer, Including Assessed Tax Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2025 0 0 monetary I D Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.
Income Loss From Continuing Operations us-gaap/2025 0 0 monetary D C Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Amount after tax of income (loss) from continuing operations attributable to the parent.
Net Income Loss Available To Common Stockholders Basic us-gaap/2025 0 0 monetary D C Net Income (Loss) Available to Common Stockholders, Basic Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
Preferred Stock Value us-gaap/2025 0 0 monetary I C Preferred Stock, Value, Issued Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
Repayments Of Convertible Debt us-gaap/2025 0 0 monetary D C Repayments of Convertible Debt The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
Stock Option Plan Expense us-gaap/2025 0 0 monetary D D Stock or Unit Option Plan Expense Amount of noncash expense for option under share-based payment arrangement.
Accounts Notes And Loans Receivable Net Current us-gaap/2024 0 0 monetary I D Accounts and Financing Receivable, after Allowance for Credit Loss, Current Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.
Cash Cash Equivalents And Restricted Cash Equivalents Period Increase Decrease Heldfor Sale Assets 0001437749-25-010730 1 0 monetary D D Net increase in cash and cash equivalents, held-for-sale assets Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage for held-for-sale assets.
Derivative Liability Issued With Notes 0001437749-25-010730 1 0 monetary D C Issuance of derivative liability in conjunction with Unsecured Convertible Notes Amount of derivative liability issued with notes.
Proceeds From Warrant Exercises us-gaap/2024 0 0 monetary D D Proceeds from Warrant Exercises The cash inflow associated with the amount received from holders exercising their stock warrants.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Disposal Group Including Discontinued Operations us-gaap/2024 0 0 monetary D D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Disposal Group, Including Discontinued Operations Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from change in exchange rate, attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalents include, but are not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.
Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity us-gaap/2024 0 0 monetary D C Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.
Operating Lease Liability Noncurrent us-gaap/2024 0 0 monetary I C Operating Lease, Liability, Noncurrent Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
Property Plant And Equipment Net us-gaap/2024 0 0 monetary I D Property, Plant and Equipment, Net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
Weighted Average Number Of Shares Outstanding Basic us-gaap/2024 0 0 shares D Weighted Average Number of Shares Outstanding, Basic Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Net Cash Provided By Used In Operating Activities us-gaap/2025 0 0 monetary D Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.
Retained Earnings Accumulated Deficit us-gaap/2025 0 0 monetary I C Retained Earnings (Accumulated Deficit) Amount of accumulated undistributed earnings (deficit).
Common Stock Value us-gaap/2025 0 0 monetary I C Common Stock, Value, Issued Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
Conversion Of Stock Amount Converted1 us-gaap/2025 0 0 monetary D D Conversion of Stock, Amount Converted The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
Stock Issued During Period Value Conversion Of Convertible Securities us-gaap/2025 0 0 monetary D C Stock Issued During Period, Value, Conversion of Convertible Securities The gross value of stock issued during the period upon the conversion of convertible securities.
Proceeds From Debenture And Warrant Issuances Net 0001437749-25-010730 1 0 monetary D D Proceeds from issuance of Secured Convertible Notes and May 2023 Warrants, net of discounts Amount of cash inflow from debenture and warrant issuances, net.
Reclassification Of Embedded Derivative Liability 0001437749-25-010730 1 0 monetary D C Reclassification of embedded derivative liability Represents the reclassification of an embedded derivative liability.

Description
Field Name Field Description
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
custom 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns.
abstract 1 if the tag is not used to represent a numeric fact.
datatype If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag.
iord If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration.
crdr If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL.
tlabel If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here.
doc The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL.

Presentation of Statements

adsh report line stmt inpth rfile tag version plabel negating
0001437749-25-017064 5 29 EQ 0 H Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition us-gaap/2025 Stock-based compensation expense related to employee and director stock awards 0
0001437749-25-010730 2 8 BS 0 H Cash And Cash Equivalents At Carrying Value us-gaap/2024 Cash and cash equivalents 0
0001437749-25-010730 2 9 BS 0 H Accounts Notes And Loans Receivable Net Current us-gaap/2024 Accounts receivable, net of allowance for credit losses ($3 at December 31, 2024 and 2023) 0
0001437749-25-010730 2 10 BS 0 H Inventory Net us-gaap/2024 Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($30 and $218 at December 31, 2024 and 2023, respectively) 0
0001437749-25-010730 2 11 BS 0 H Prepaid Expense And Other Assets Current us-gaap/2024 Prepaid expenses and other current assets 0
0001437749-25-010730 2 12 BS 0 H Assets Held For Sale Not Part Of Disposal Group Current Other us-gaap/2024 Current assets, held-for-sale 0
0001437749-25-010730 2 13 BS 0 H Assets Of Disposal Group Including Discontinued Operation Current us-gaap/2024 Current assets, discontinued operations 0
0001437749-25-010730 2 14 BS 0 H Assets Current us-gaap/2024 Total current assets 0
0001437749-25-010730 2 15 BS 0 H Operating Lease Right Of Use Asset us-gaap/2024 Operating lease right-of-use assets 0
0001437749-25-010730 2 16 BS 0 H Property Plant And Equipment Net us-gaap/2024 Property and equipment, net 0
0001437749-25-010730 2 17 BS 0 H Other Assets Noncurrent us-gaap/2024 Other assets 0
0001437749-25-010730 2 18 BS 0 H Disposal Group Including Discontinued Operation Assets Noncurrent us-gaap/2024 Other assets, discontinued operations 0
0001437749-25-010730 2 19 BS 0 H Assets us-gaap/2024 TOTAL ASSETS 0
0001437749-25-010730 2 21 BS 0 H Accounts Payable Current us-gaap/2024 Accounts payable 0
0001437749-25-010730 2 22 BS 0 H Accrued Liabilities Current us-gaap/2024 Accrued liabilities 0
0001437749-25-010730 2 23 BS 0 H Notes Payable Current us-gaap/2024 Bridge Loan 0
0001437749-25-010730 2 24 BS 0 H Unsecured Debt Current us-gaap/2024 Unsecured Convertible Notes, net of discounts 0
0001437749-25-010730 2 25 BS 0 H Convertible Debt Current us-gaap/2024 Secured Convertible Notes, net of discounts 0
0001437749-25-010730 2 26 BS 0 H Operating Lease Liability Current us-gaap/2024 Operating lease liabilities 0
0001437749-25-010730 2 27 BS 0 H Liabilities Of Disposal Group Including Discontinued Operation Current us-gaap/2024 Current liabilities, discontinued operations 0
0001437749-25-010730 2 28 BS 0 H Liabilities Current us-gaap/2024 Total current liabilities 0
0001437749-25-010730 2 29 BS 0 H Derivative Liabilities Noncurrent us-gaap/2024 Warrant liability 0
0001437749-25-010730 2 30 BS 0 H Operating Lease Liability Noncurrent us-gaap/2024 Operating lease liabilities-non-current 0
0001437749-25-010730 2 31 BS 0 H Liabilities us-gaap/2024 Total liabilities 0
0001437749-25-010730 2 32 BS 0 H Commitments And Contingencies us-gaap/2024 Commitments and Contingencies 0
0001437749-25-010730 2 34 BS 0 H Preferred Stock Value us-gaap/2024 Preferred Stock 0
0001437749-25-010730 2 35 BS 0 H Common Stock Value us-gaap/2024 Common stock, $0.01 par value; 150,000 shares authorized, 4,885 and 321 shares issued and outstanding at December 31, 2024 and 2023, respectively 0
0001437749-25-010730 2 36 BS 0 H Additional Paid In Capital us-gaap/2024 Additional paid-in capital 0
0001437749-25-010730 2 37 BS 0 H Retained Earnings Accumulated Deficit us-gaap/2024 Accumulated deficit 0
0001437749-25-010730 2 38 BS 0 H Stockholders Equity us-gaap/2024 Total stockholders equity 0
0001437749-25-010730 2 39 BS 0 H Liabilities And Stockholders Equity us-gaap/2024 TOTAL LIABILITIES AND STOCKHOLDERS EQUITY 0
0001437749-25-010730 3 7 BS 1 H Allowance For Doubtful Accounts Receivable Current us-gaap/2024 Accounts Receivable, Allowance for Credit Loss, Current 0
0001437749-25-010730 3 8 BS 1 H Inventory Valuation Reserves Including Disposal And Discontinued Operations 0001437749-25-010730 Inventory, allowance 0
0001437749-25-010730 3 9 BS 1 H Preferred Stock Par Or Stated Value Per Share us-gaap/2024 Preferred Stock, Par or Stated Value Per Share (in dollars per share) 0
0001437749-25-010730 3 10 BS 1 H Preferred Stock Shares Authorized us-gaap/2024 Preferred Stock, Shares Authorized (in shares) 0
0001437749-25-010730 3 11 BS 1 H Preferred Stock Shares Outstanding us-gaap/2024 Preferred Stock, Shares Outstanding (in shares) 0
0001437749-25-010730 3 12 BS 1 H Preferred Stock Shares Issued us-gaap/2024 Preferred Stock, Shares Issued (in shares) 0
0001437749-25-010730 3 13 BS 1 H Common Stock Par Or Stated Value Per Share us-gaap/2024 Common Stock, Par or Stated Value Per Share (in dollars per share) 0
0001437749-25-010730 3 14 BS 1 H Common Stock Shares Authorized us-gaap/2024 Common Stock, Shares Authorized (in shares) 0
0001437749-25-010730 3 15 BS 1 H Common Stock Shares Issued us-gaap/2024 Common Stock, Shares, Issued (in shares) 0
0001437749-25-010730 3 16 BS 1 H Common Stock Shares Outstanding us-gaap/2024 Common Stock, Shares, Outstanding (in shares) 0
0001437749-25-010730 4 8 IS 0 H Revenue From Contract With Customer Including Assessed Tax us-gaap/2024 Total sales, net 0
0001437749-25-010730 4 9 IS 0 H Cost Of Goods And Services Sold us-gaap/2024 Cost of goods sold 0
0001437749-25-010730 4 10 IS 0 H Gross Profit us-gaap/2024 Gross profit 0
0001437749-25-010730 4 12 IS 0 H Research And Development Expense us-gaap/2024 Research and development 0
0001437749-25-010730 4 13 IS 0 H Selling And Marketing Expense us-gaap/2024 Sales and marketing 0
0001437749-25-010730 4 14 IS 0 H General And Administrative Expense us-gaap/2024 General and administrative 0
0001437749-25-010730 4 15 IS 0 H Gain Loss On Sale Of Business us-gaap/2024 Loss on divestiture of subsidiary 1
0001437749-25-010730 4 16 IS 0 H Operating Expenses us-gaap/2024 Total operating expenses 0
0001437749-25-010730 4 17 IS 0 H Operating Income Loss us-gaap/2024 Operating loss 0
0001437749-25-010730 4 18 IS 0 H Fair Value Adjustment Of Warrants us-gaap/2024 Non-cash gain on changes in fair value of warrant liability 1
0001437749-25-010730 4 19 IS 0 H Gains Losses On Extinguishment Of Debt us-gaap/2024 Extinguishment of Secured Convertible Note 0
0001437749-25-010730 4 20 IS 0 H Noncash Gain On Changes In Combined Derivative Liability 0001437749-25-010730 Non-cash (loss) gain on changes in fair value of embedded derivative liability 1
0001437749-25-010730 4 21 IS 0 H Amortization Of Financing Costs And Discounts us-gaap/2024 Accretion of interest and amortization of discounts on convertible notes 1
0001437749-25-010730 4 22 IS 0 H Gain Loss On Modification Of Warrants 0001437749-25-010730 Non-cash loss on modification of common stock warrants 0
0001437749-25-010730 4 23 IS 0 H Other Nonoperating Income Expense us-gaap/2024 Other expense, net 0
0001437749-25-010730 4 24 IS 0 H Income Loss From Continuing Operations us-gaap/2024 Net loss from continuing operations 0
0001437749-25-010730 4 25 IS 0 H Income Loss From Heldfor Sale Assets 0001437749-25-010730 Net income from held-for-sale assets (Note 22) 0
0001437749-25-010730 4 26 IS 0 H Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity us-gaap/2024 Net loss from discontinued operations (Note 21) 0
0001437749-25-010730 4 27 IS 0 H Net Income Loss us-gaap/2024 Net loss 0
0001437749-25-010730 4 28 IS 0 H Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount us-gaap/2024 Less: Increase to accumulated deficit due to adjustment to common stock warrants exercise price 1
0001437749-25-010730 4 29 IS 0 H Preferred Stock Convertible Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount us-gaap/2024 Less: Increase to accumulated deficit due to adjustment to Preferred Stock conversion prices 1
0001437749-25-010730 4 30 IS 0 H Net Income Loss Available To Common Stockholders Basic us-gaap/2024 Net loss attributable to common stockholders 0
0001437749-25-010730 4 31 IS 0 H Income Loss From Continuing Operations Per Basic Share us-gaap/2024 Loss per share from continuing operations (in dollars per share) 0
0001437749-25-010730 4 32 IS 0 H Income Loss From Discontinued Operations Net Of Tax Per Basic Share us-gaap/2024 Loss per share from held-for-sale assets and discontinued operation (in dollars per share) 0
0001437749-25-010730 4 33 IS 0 H Earnings Per Share Basic us-gaap/2024 Net loss per share attributable to common stockholders (basic and diluted) (in dollars per share) 0
0001437749-25-010730 4 34 IS 0 H Weighted Average Number Of Shares Outstanding Basic us-gaap/2024 Weighted-average shares of common stock used in computing net loss per share attributable to common stockholders (basic and diluted) (in shares) 0
0001437749-25-010730 5 31 EQ 0 H Shares Outstanding us-gaap/2024 Balance (in shares) 0
0001437749-25-010730 5 32 EQ 0 H Stockholders Equity us-gaap/2024 Balance 0
0001437749-25-010730 5 33 EQ 0 H Net Income Loss us-gaap/2024 Net loss 0
0001437749-25-010730 5 34 EQ 0 H Stock Issued During Period Shares Conversion Of Convertible Securities us-gaap/2024 Conversion of Preferred Stock to common stock (in shares) 0
0001437749-25-010730 5 35 EQ 0 H Stock Issued During Period Value Conversion Of Convertible Securities us-gaap/2024 Conversion of Preferred Stock to common stock 0
0001437749-25-010730 5 36 EQ 0 H Adjustments To Additional Paid In Capital Down Round Feature Adjustment Related To Preferred Stock 0001437749-25-010730 Adjustment of Preferred Stock conversion price 0
0001437749-25-010730 5 37 EQ 0 H Adjustments To Additional Paid In Capital Modification Of Warrant 0001437749-25-010730 Modification of common stock warrants 0
0001437749-25-010730 5 38 EQ 0 H Adjustments To Additional Paid In Capital Reclassifications Of Warrants 0001437749-25-010730 Reclassification of May 2023 Warrants 0
0001437749-25-010730 5 39 EQ 0 H Reclassification Of Embedded Derivative Liability 0001437749-25-010730 Reclassification of embedded derivative liability 0
0001437749-25-010730 5 40 EQ 0 H Stock Issued In Connection With Exercise Of Warrants Shares 0001437749-25-010730 Issuance of common stock in connection with Warrant Reprice Transaction, net (in shares) 0
0001437749-25-010730 5 41 EQ 0 H Stock Issued In Connection With Exercise Of Warrants Value 0001437749-25-010730 Issuance of common stock in connection with Warrant Reprice Transaction, net 0
0001437749-25-010730 5 42 EQ 0 H Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition us-gaap/2024 Stock-based compensation expense related to employee and director stock awards 0
0001437749-25-010730 5 43 EQ 0 H Reclassify Private Placement Warrants 0001437749-25-010730 Reclassification of Warrants from liability 0
0001437749-25-010730 5 44 EQ 0 H Stock Issued During Period Shares Reverse Stock Splits us-gaap/2024 Shares issued for 35:1 reverse stock split due to rounding feature (in shares) 0
0001437749-25-010730 5 45 EQ 0 H Stock Issued During Period Value Reverse Stock Splits 0001437749-25-010730 Shares issued for 35:1 reverse stock split due to rounding feature 0
0001437749-25-010730 5 46 EQ 0 H Equity Issued During Period Shares And Warrants New Issues 0001437749-25-010730 Issuance of common stock and pre-funded warrants in the 2024 Public Offering, net of issuance cost (in shares) 0
0001437749-25-010730 5 47 EQ 0 H Equity Issued During Period Value New Issues 0001437749-25-010730 Issuance of common stock and pre-funded warrants in the 2024 Public Offering, net of issuance cost 0
0001437749-25-010730 5 48 EQ 0 H Shares Outstanding us-gaap/2024 Balance (in shares) 0
0001437749-25-010730 5 49 EQ 0 H Stockholders Equity us-gaap/2024 Balance 0
0001437749-25-010730 6 6 EQ 1 H Stockholders Equity Note Stock Split Conversion Ratio1 us-gaap/2024 Stockholders' Equity Note, Stock Split, Conversion Ratio 0
0001437749-25-010730 7 19 CF 0 H Net Income Loss us-gaap/2024 Net loss 0
0001437749-25-010730 7 20 CF 0 H Income Loss From Heldfor Sale Assets 0001437749-25-010730 Net income from held-for-sale assets 1
0001437749-25-010730 7 21 CF 0 H Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity us-gaap/2024 Net loss from discontinued operations 1
0001437749-25-010730 7 23 CF 0 H Depreciation us-gaap/2024 Depreciation of property and equipment 0
0001437749-25-010730 7 24 CF 0 H Stock Option Plan Expense us-gaap/2024 Stock-based compensation expense related to employee and director stock awards 0
0001437749-25-010730 7 25 CF 0 H Gain Loss On Sale Of Business us-gaap/2024 Non-cash loss on divestiture of subsidiary 0
0001437749-25-010730 7 26 CF 0 H Gains Losses On Extinguishment Of Debt us-gaap/2024 Extinguishment of Secured Convertible Note 0
0001437749-25-010730 7 27 CF 0 H Noncash Expense Incurred To Obtain Consent Of Secured Note Holders 0001437749-25-010730 Non-cash expense incurred to obtain consent of Secured Convertible Note holders 0
0001437749-25-010730 7 28 CF 0 H Modification Of Warrants 0001437749-25-010730 Modification of common stock warrants, included in Other expense 0
0001437749-25-010730 7 29 CF 0 H Fair Value Adjustment Of Warrants us-gaap/2024 Non-cash gain on changes in fair value of warrant liability 0
0001437749-25-010730 7 30 CF 0 H Noncash Gain On Changes In Combined Derivative Liability 0001437749-25-010730 Non-cash loss (gain) on changes in fair value of embedded derivative liability 0
0001437749-25-010730 7 31 CF 0 H Operating Lease Right Of Use Asset Amortization Expense us-gaap/2024 Non-cash right-of-use amortization 0
0001437749-25-010730 7 32 CF 0 H Amortization Of Debt Discount Premium us-gaap/2024 Accretion of interest and amortization of debt discounts on convertible notes 0
0001437749-25-010730 7 34 CF 0 H Increase Decrease In Accounts Receivable us-gaap/2024 Accounts receivable 1
0001437749-25-010730 7 35 CF 0 H Increase Decrease In Inventories us-gaap/2024 Inventory 1
0001437749-25-010730 7 36 CF 0 H Increase Decrease In Prepaid Deferred Expense And Other Assets us-gaap/2024 Prepaid expenses and other current assets 1
0001437749-25-010730 7 37 CF 0 H Increase Decrease In Other Operating Assets us-gaap/2024 Other assets 1
0001437749-25-010730 7 38 CF 0 H Increase Decrease In Accounts Payable And Accrued Liabilities us-gaap/2024 Accounts payable and accrued liabilities 0
0001437749-25-010730 7 39 CF 0 H Increase Decrease In Operating Lease Liability us-gaap/2024 Operating lease liabilities 0
0001437749-25-010730 7 40 CF 0 H Net Cash Provided By Used In Operating Activities Continuing Operations us-gaap/2024 Net cash used in operating activities, continuing operations 0
0001437749-25-010730 7 42 CF 0 H Proceeds From Divestiture Of Businesses us-gaap/2024 Proceeds from divestiture of subsidiary 0
0001437749-25-010730 7 43 CF 0 H Payments To Acquire Property Plant And Equipment us-gaap/2024 Purchases of property and equipment 1
0001437749-25-010730 7 44 CF 0 H Net Cash Provided By Used In Investing Activities us-gaap/2024 Net cash provided by (used in) investing activities, continuing operations 0
0001437749-25-010730 7 46 CF 0 H Proceeds From Warrant Exercises us-gaap/2024 Proceeds from Warrants Exercise 0
0001437749-25-010730 7 47 CF 0 H Proceeds From Issuance Or Sale Of Equity us-gaap/2024 Proceeds from issuance of common stock and pre-funded warrants the 2024 Public Offering, net of issuance costs 0
0001437749-25-010730 7 48 CF 0 H Proceeds From Notes Payable us-gaap/2024 Proceeds from Bridge Loan 0
0001437749-25-010730 7 49 CF 0 H Proceeds From Debenture And Warrant Issuances Net 0001437749-25-010730 Proceeds from issuance of Secured Convertible Notes and May 2023 Warrants, net of discounts 0
0001437749-25-010730 7 50 CF 0 H Repayments Of Convertible Debt us-gaap/2024 Payments on Secured Convertible Notes 1
0001437749-25-010730 7 51 CF 0 H Payments Of Debt Issuance Costs us-gaap/2024 Cash debt issuance cost 1
0001437749-25-010730 7 52 CF 0 H Net Cash Provided By Used In Financing Activities us-gaap/2024 Net cash provided by financing activities, continuing operations 0
0001437749-25-010730 7 53 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations us-gaap/2024 Net decrease in cash, cash equivalents, and restricted cash, continuing operations 0
0001437749-25-010730 7 54 CF 0 H Cash Cash Equivalents And Restricted Cash Equivalents Period Increase Decrease Heldfor Sale Assets 0001437749-25-010730 Net increase in cash and cash equivalents, held-for-sale assets 0
0001437749-25-010730 7 55 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Disposal Group Including Discontinued Operations us-gaap/2024 Net decrease in cash and cash equivalents, discontinued operations 0
0001437749-25-010730 7 56 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2024 Net decrease in cash, cash equivalents and restricted cash, consolidated 0
0001437749-25-010730 7 57 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations us-gaap/2024 Cash, cash equivalents and restricted cash, beginning of year 0
0001437749-25-010730 7 58 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations us-gaap/2024 Less: Cash and cash equivalents of discontinued operations, end of period 1
0001437749-25-010730 7 59 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Cash, cash equivalents and restricted cash of continuing operations, end of year 0
0001437749-25-010730 7 61 CF 0 H Interest Paid Net us-gaap/2024 Interest paid in continuing operations 0
0001437749-25-010730 7 62 CF 0 H Interest Paid Discontinued Operations us-gaap/2024 Interest paid in discontinued operations 0
0001437749-25-010730 7 63 CF 0 H Conversion Of Stock Amount Converted1 us-gaap/2024 Conversions of preferred stock to common stock 0
0001437749-25-010730 7 64 CF 0 H Down Round Feature Adjustments Related To Preferred Stock 0001437749-25-010730 Down round feature adjustments related to preferred stock 0
0001437749-25-010730 7 65 CF 0 H Down Round Feature Adjustments Related To Common Stock Warrants 0001437749-25-010730 Down round feature adjustments related to common stock warrants 0
0001437749-25-010730 7 66 CF 0 H Derivative Liability Issued With Notes 0001437749-25-010730 Issuance of derivative liability in conjunction with Unsecured Convertible Notes 0
0001437749-25-010730 7 67 CF 0 H Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity us-gaap/2024 Warrant liabilities transferred to equity 0
0001437749-25-017064 2 7 BS 0 H Cash And Cash Equivalents At Carrying Value us-gaap/2025 Cash and cash equivalents 0
0001437749-25-017064 2 8 BS 0 H Prepaid Expense And Other Assets Current us-gaap/2025 Prepaid expenses and other current assets 0
0001437749-25-017064 2 9 BS 0 H Assets Of Disposal Group Including Discontinued Operation Current us-gaap/2025 Current assets, discontinued operations 0
0001437749-25-017064 2 10 BS 0 H Assets Current us-gaap/2025 Total current assets 0
0001437749-25-017064 2 11 BS 0 H Operating Lease Right Of Use Asset us-gaap/2025 Operating lease right-of-use assets 0
0001437749-25-017064 2 12 BS 0 H Property Plant And Equipment Net us-gaap/2025 Property and equipment, net 0
0001437749-25-017064 2 13 BS 0 H Other Assets Noncurrent us-gaap/2025 Other assets 0
0001437749-25-017064 2 14 BS 0 H Disposal Group Including Discontinued Operation Assets Noncurrent us-gaap/2025 Other assets, discontinued operations 0
0001437749-25-017064 2 15 BS 0 H Assets us-gaap/2025 TOTAL ASSETS 0
0001437749-25-017064 2 17 BS 0 H Accounts Payable Current us-gaap/2025 Accounts payable 0
0001437749-25-017064 2 18 BS 0 H Accrued Liabilities Current us-gaap/2025 Accrued liabilities 0
0001437749-25-017064 2 19 BS 0 H Notes Payable Current us-gaap/2025 Bridge Loan 0
0001437749-25-017064 2 20 BS 0 H Unsecured Debt Current us-gaap/2025 Unsecured Convertible Notes, net of discounts 0
0001437749-25-017064 2 21 BS 0 H Operating Lease Liability Current us-gaap/2025 Operating lease liabilities 0
0001437749-25-017064 2 22 BS 0 H Liabilities Of Disposal Group Including Discontinued Operation Current us-gaap/2025 Current liabilities, discontinued operations 0
0001437749-25-017064 2 23 BS 0 H Liabilities Current us-gaap/2025 Total current liabilities 0
0001437749-25-017064 2 24 BS 0 H Operating Lease Liability Noncurrent us-gaap/2025 Operating lease liabilities-non-current 0
0001437749-25-017064 2 25 BS 0 H Liabilities us-gaap/2025 Total liabilities 0
0001437749-25-017064 2 26 BS 0 H Commitments And Contingencies us-gaap/2025 Commitments and Contingencies 0
0001437749-25-017064 2 28 BS 0 H Preferred Stock Value us-gaap/2025 Preferred stock, $0.01 par value; 5,000 shares authorized; Series B Preferred Stock; 1 shares issued and outstanding at March 31, 2025 and December 31, 2024 0
0001437749-25-017064 2 29 BS 0 H Common Stock Value us-gaap/2025 Common stock, $0.01 par value; 150,000 shares authorized, 5,816 and 4,885 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively 0
0001437749-25-017064 2 30 BS 0 H Additional Paid In Capital us-gaap/2025 Additional paid-in capital 0
0001437749-25-017064 2 31 BS 0 H Retained Earnings Accumulated Deficit us-gaap/2025 Accumulated deficit 0
0001437749-25-017064 2 32 BS 0 H Stockholders Equity us-gaap/2025 Total stockholders equity (deficit) 0
0001437749-25-017064 2 33 BS 0 H Liabilities And Stockholders Equity us-gaap/2025 TOTAL LIABILITIES AND STOCKHOLDERS EQUITY (DEFICIT) 0
0001437749-25-017064 3 6 BS 1 H Preferred Stock Par Or Stated Value Per Share us-gaap/2025 Preferred stock par value (in dollars per share) 0
0001437749-25-017064 3 7 BS 1 H Preferred Stock Shares Authorized us-gaap/2025 Preferred stock, shares authorized (in shares) 0
0001437749-25-017064 3 8 BS 1 H Preferred Stock Shares Issued us-gaap/2025 Preferred stock, shares issued (in shares) 0
0001437749-25-017064 3 9 BS 1 H Preferred Stock Shares Outstanding us-gaap/2025 Preferred stock, shares outstanding (in shares) 0
0001437749-25-017064 3 10 BS 1 H Common Stock Par Or Stated Value Per Share us-gaap/2025 Common stock, par value (in dollars per share) 0
0001437749-25-017064 3 11 BS 1 H Common Stock Shares Authorized us-gaap/2025 Common stock, shares authorized (in shares) 0
0001437749-25-017064 3 12 BS 1 H Common Stock Shares Outstanding us-gaap/2025 Common stock, shares outstanding (in shares) 0
0001437749-25-017064 3 13 BS 1 H Common Stock Shares Issued us-gaap/2025 Common stock, shares issued (in shares) 0
0001437749-25-017064 4 4 IS 0 H General And Administrative Expense us-gaap/2025 General and administrative 0
0001437749-25-017064 4 5 IS 0 H Impairment Of Long Lived Assets Held For Use us-gaap/2025 Impairment of long-lived assets 0
0001437749-25-017064 4 6 IS 0 H Operating Expenses us-gaap/2025 Total operating expenses 0
0001437749-25-017064 4 7 IS 0 H Operating Income Loss us-gaap/2025 Operating loss 0
0001437749-25-017064 4 8 IS 0 H Fair Value Adjustment Of Warrants us-gaap/2025 Non-cash gain on changes in fair value of warrant liability 1
0001437749-25-017064 4 9 IS 0 H Noncash Gain On Changes In Combined Derivative Liability 0001437749-25-017064 Non-cash gain on changes in fair value of embedded derivative liability 1
0001437749-25-017064 4 10 IS 0 H Amortization Of Financing Costs And Discounts us-gaap/2025 Accretion of interest and amortization of discounts on convertible notes 1
0001437749-25-017064 4 11 IS 0 H Other Nonoperating Income Expense us-gaap/2025 Other expense, net 0
0001437749-25-017064 4 12 IS 0 H Income Loss From Continuing Operations us-gaap/2025 Net loss from continuing operations 0
0001437749-25-017064 4 13 IS 0 H Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity us-gaap/2025 Net income (loss) from discontinued operations, net of taxes (Notes 14, 15 and 16) 0
0001437749-25-017064 4 14 IS 0 H Net Income Loss us-gaap/2025 Net income (loss) 0
0001437749-25-017064 4 15 IS 0 H Preferred Stock Convertible Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount us-gaap/2025 Less: Increase to accumulated deficit due to adjustment to Preferred Stock conversion prices 0
0001437749-25-017064 4 16 IS 0 H Net Income Loss Available To Common Stockholders Basic us-gaap/2025 Net income (loss) attributable to common stockholders 0
0001437749-25-017064 4 17 IS 0 H Weighted Average Number Of Shares Outstanding Basic us-gaap/2025 Basic (and diluted for net loss) (in shares) 0
0001437749-25-017064 4 18 IS 0 H Weighted Average Number Of Diluted Shares Outstanding us-gaap/2025 Diluted for net income (in shares) 0
0001437749-25-017064 4 20 IS 0 H Income Loss From Continuing Operations Per Basic Share us-gaap/2025 Basic loss per share from continuing operations (in dollars per share) 0
0001437749-25-017064 4 21 IS 0 H Income Loss From Discontinued Operations Net Of Tax Per Basic Share us-gaap/2025 Basic earnings (loss) per share from discontinued operations (in dollars per share) 0
0001437749-25-017064 4 22 IS 0 H Earnings Per Share Basic us-gaap/2025 Basic earnings (loss) per share attributable to common stockholders (in dollars per share) 0
0001437749-25-017064 4 23 IS 0 H Income Loss From Continuing Operations Per Diluted Share us-gaap/2025 Diluted earnings (loss) per share from continuing operations (in dollars per share) 0
0001437749-25-017064 4 24 IS 0 H Income Loss From Discontinued Operations Net Of Tax Per Diluted Share us-gaap/2025 Diluted earnings (loss) per share from discontinued operations (in dollars per share) 0
0001437749-25-017064 4 25 IS 0 H Earnings Per Share Diluted us-gaap/2025 Diluted earnings (loss) per share attributable to common stockholders (in dollars per share) 0
0001437749-25-017064 5 23 EQ 0 H Shares Outstanding us-gaap/2025 Balance (in shares) 0
0001437749-25-017064 5 24 EQ 0 H Stockholders Equity us-gaap/2025 Balance 0
0001437749-25-017064 5 25 EQ 0 H Net Income Loss us-gaap/2025 Net loss 0
0001437749-25-017064 5 26 EQ 0 H Stock Issued In Connection With Exercise Of Warrants Shares 0001437749-25-017064 Stock Issued In Connection with Exercise of Warrants, Shares (in shares) 0
0001437749-25-017064 5 27 EQ 0 H Stock Issued In Connection With Exercise Of Warrants Value 0001437749-25-017064 Stock Issued In Connection with Exercise of Warrants, Value 0
0001437749-25-017064 5 28 EQ 0 H Adjustments To Additional Paid In Capital Warrant Repurchase 0001437749-25-017064 Repurchase of warrants 1
0001437749-25-017064 5 30 EQ 0 H Shares Outstanding us-gaap/2025 Balance (in shares) 0
0001437749-25-017064 5 31 EQ 0 H Stockholders Equity us-gaap/2025 Balance 0
0001437749-25-017064 5 32 EQ 0 H Stock Issued During Period Shares Conversion Of Convertible Securities us-gaap/2025 Conversion of Preferred Stock to common stock (in shares) 0
0001437749-25-017064 5 33 EQ 0 H Stock Issued During Period Value Conversion Of Convertible Securities us-gaap/2025 Conversion of Preferred Stock to common stock 0
0001437749-25-017064 5 34 EQ 0 H Adjustments To Additional Paid In Capital Down Round Feature Adjustment Related To Preferred Stock 0001437749-25-017064 Adjustment of Preferred Stock conversion price 0
0001437749-25-017064 6 7 CF 0 H Net Income Loss us-gaap/2025 Net loss 0
0001437749-25-017064 6 8 CF 0 H Loss Income From Discontinued Operations Net Of Tax Attributable To Parent 0001437749-25-017064 Net (income) loss from discontinued operations, net of taxes 0
0001437749-25-017064 6 10 CF 0 H Depreciation us-gaap/2025 Depreciation of property and equipment 0
0001437749-25-017064 6 11 CF 0 H Stock Option Plan Expense us-gaap/2025 Stock-based compensation expense related to employee and director stock awards 0
0001437749-25-017064 6 12 CF 0 H Noncash Expense Incurred To Obtain Consent Of Secured Note Holders 0001437749-25-017064 Non-cash expense incurred to obtain consent of Secured Convertible Note holders 0
0001437749-25-017064 6 13 CF 0 H Fair Value Adjustment Of Warrants us-gaap/2025 Non-cash gain on changes in fair value of warrant liability 0
0001437749-25-017064 6 14 CF 0 H Noncash Gain On Changes In Combined Derivative Liability 0001437749-25-017064 Non-cash gain on changes in fair value of embedded derivative liability 0
0001437749-25-017064 6 15 CF 0 H Operating Lease Right Of Use Asset Amortization Expense us-gaap/2025 Non-cash right-of-use asset amortization 0
0001437749-25-017064 6 16 CF 0 H Impairment Of Long Lived Assets Held For Use us-gaap/2025 Impairment of long-lived assets 0
0001437749-25-017064 6 17 CF 0 H Amortization Of Debt Discount Premium us-gaap/2025 Accretion of interest and amortization of debt discounts on convertible notes 0
0001437749-25-017064 6 19 CF 0 H Increase Decrease In Accounts Receivable us-gaap/2025 Accounts receivable 1
0001437749-25-017064 6 20 CF 0 H Increase Decrease In Inventories us-gaap/2025 Inventory 1
0001437749-25-017064 6 21 CF 0 H Increase Decrease In Prepaid Deferred Expense And Other Assets us-gaap/2025 Prepaid expenses and other current assets 1
0001437749-25-017064 6 22 CF 0 H Increase Decrease In Other Operating Assets us-gaap/2025 Other assets 1
0001437749-25-017064 6 23 CF 0 H Increase Decrease In Accounts Payable And Accrued Liabilities us-gaap/2025 Accounts payable and accrued liabilities 0
0001437749-25-017064 6 24 CF 0 H Increase Decrease In Operating Lease Liability us-gaap/2025 Operating lease liabilities 0
0001437749-25-017064 6 25 CF 0 H Net Cash Provided By Used In Operating Activities us-gaap/2025 Net cash used in operating activities, continuing operations 0
0001437749-25-017064 6 27 CF 0 H Payments To Acquire Property Plant And Equipment us-gaap/2025 Purchases of property and equipment 1
0001437749-25-017064 6 28 CF 0 H Net Cash Provided By Used In Investing Activities us-gaap/2025 Net cash used in investing activities, continuing operations 0
0001437749-25-017064 6 30 CF 0 H Proceeds From Warrant Exercises us-gaap/2025 Proceeds from warrant exercises 0
0001437749-25-017064 6 31 CF 0 H Repayments Of Convertible Debt us-gaap/2025 Payments on Secured Convertible Notes 1
0001437749-25-017064 6 32 CF 0 H Payments For Repurchase Of Warrants us-gaap/2025 Warrant repurchases 1
0001437749-25-017064 6 33 CF 0 H Repayments Of Notes Payable us-gaap/2025 Payment on Bridge Note 1
0001437749-25-017064 6 34 CF 0 H Payments Of Debt Issuance Costs us-gaap/2025 Cash debt issuance cost 1
0001437749-25-017064 6 35 CF 0 H Net Cash Provided By Used In Financing Activities us-gaap/2025 Net cash used in financing activities, continuing operations 0
0001437749-25-017064 6 36 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations us-gaap/2025 Net decrease in cash, cash equivalents, and restricted cash, continuing operations 0
0001437749-25-017064 6 37 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Disposal Group Including Discontinued Operations us-gaap/2025 Net increase in cash and cash equivalents, discontinued operations 0
0001437749-25-017064 6 38 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2025 Net increase (decrease) in cash, cash equivalents, and restricted cash, consolidated 0
0001437749-25-017064 6 39 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2025 Cash, cash equivalents and restricted cash, beginning of period 0
0001437749-25-017064 6 40 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations us-gaap/2025 Cash, cash equivalents and restricted cash of continuing operations, end of period 0
0001437749-25-017064 6 42 CF 0 H Interest Paid Net us-gaap/2025 Interest paid 0
0001437749-25-017064 6 44 CF 0 H Conversion Of Stock Amount Converted1 us-gaap/2025 Conversions of preferred stock to common stock 0
0001437749-25-017064 6 45 CF 0 H Down Round Feature Adjustments Related To Preferred Stock 0001437749-25-017064 Down round feature adjustments related to preferred stock 0
0001437749-25-017064 6 46 CF 0 H Derivative Liability Issued With Notes 0001437749-25-017064 Issuance of derivative liability in conjunction with Unsecured Convertible Notes 0

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
report Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site.
line Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived.
stmt The financial statement location to which the value of the “report” field pertains.
inpth Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700.
rfile The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file.
tag The tag chosen by the filer for this line item.
version The taxonomy identifier if the tag is a standard tag, otherwise adsh.
plabel The text presented on the line item, also known as a “preferred” label.
negating Flag to indicate whether the plabel is negating.